Systems and methods for accurate and repeatable delivery of active pharmaceutical ingredients - Patents.com
The method of continuous microdroplet delivery with imaging ensures accurate and repeatable dosing of APIs in food products, addressing inconsistencies and enhancing user experience by maintaining consistent medicinal effects.
Patent Information
- Application Number
- JP2024522667
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2021-09-14
- Filing Date
- 2022-09-14
- Publication Date
- 2024-11-26
AI Technical Summary
Existing methods for adding active pharmaceutical ingredients (APIs) to food products suffer from inaccuracies and inconsistencies in dosing, leading to varying medicinal effects across different regions of the same food product, especially in bite-sized items.
A method involving the continuous delivery of microdroplets of API-containing liquid, with imaging and volume determination to ensure precise and consistent dosing, using a system with a dosing head and imaging system to monitor and adjust the delivery process.
Achieves accurate and repeatable dosing of APIs, ensuring consistent medicinal effects across different parts of the food product, reducing variations and enhancing user experience.
Smart Images

Figure 2024543789000001_ABST
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Patent Application No. 63 / 244,031, filed September 14, 2021, the disclosure of which is incorporated by reference herein as if set forth in its entirety. [Background technology]
[0002] [Technical field] The present disclosure relates to the field of active pharmaceutical ingredients, including cannabis, and methods and systems for ensuring accurate and repeatable dosing thereof.
[0003] [Discussion of the current state of the art] The legal cannabis industry is growing rapidly in the United States, Canada, and around the world. Cannabis, or other active pharmaceutical ingredients (API), are typically included in batch-produced foods or are added after the food is fully prepared. Foods are sold with various doses of API indicated on the label of the package. Thus, achieving dose accuracy, where the food contains the indicated dose, is a known objective. Also, achieving dose repeatability, where different portions of the same food contain substantially the same dose, is another known objective. Dose accuracy and repeatability provide the user with a predictable user experience when the food is consumed or otherwise used.
[0004] Although the market often claims that both objectives are achieved using conventional dispensing techniques, large variations in both dosage accuracy and dosage repeatability are common. As a result, the medicinal effect experienced when consuming one piece of personalized food is significantly different from the medicinal effect experienced when consuming another piece of the same personalized food. This difference can have a large impact when the food is bite-sized. When the food is larger than bite-sized, the variation in API loading can further cause the first region of the food to contain substantially more or less API than the second region of the food. Thus, the medicinal effect experienced when consuming the first region of the food is significantly different from the medicinal effect experienced when consuming the second region of the food. Summary of the Invention [Problem to be solved by the invention]
[0005] Therefore, what is needed is a method and apparatus for reliably achieving dosage accuracy and consistency. [Means for solving the problem]
[0006] In one embodiment, a method for limiting the error rate in a cannabinoid dosing system is provided. The method may include continuously delivering microdroplets of liquid from at least one dosing head along a path to a substrate, the liquid containing a quantity of cannabinoids. The method may further include imaging the continuously delivered microdroplets at a location along the path between the at least one dosing head and the substrate. Based on the imaging step, the method may include determining a total volume of liquid delivered to the substrate.
[0007] The following detailed description will be better understood when read in conjunction with the accompanying drawings, in which are shown by way of illustration example embodiments, with the understanding, however, that the disclosure is not limited to the precise arrangements and instrumentalities shown. [Brief description of the drawings]
[0008] [Figure 1A] FIG. 1 is a schematic perspective view of an apparatus for delivering microdroplets of an active pharmaceutical ingredient to a substrate, such as an edible product. [Figure 1B] FIG. 1B is an enlarged schematic perspective view of a portion of the edible product shown in FIG. 1A. [Figure 2A] FIG. 1B is a schematic diagram of the addition zone of the system shown in FIG. 1A. [Figure 2B] FIG. 2 is a perspective view of a microdroplet in one embodiment. [Figure 2C] FIG. 2 is a side view of a microdroplet in one embodiment. [Diagram 3] FIG. 1B is a top view of the edible product shown in FIG. 1A showing the delivery zone. [Figure 4A] FIG. 1 is a perspective view of mixed nuts loaded with active pharmaceutical ingredients according to an embodiment of the present disclosure. [Figure 4B] FIG. 1 is a perspective view of a dried fruit loaded with an active pharmaceutical ingredient according to an embodiment of the present disclosure. [Figure 4C] FIG. 1 is a perspective view of a baked good to which has been added an active pharmaceutical ingredient according to an embodiment of the present disclosure. [Figure 4D] FIG. 1 is a side view of a gummy candy loaded with an active pharmaceutical ingredient according to an embodiment of the present disclosure. [Figure 4E] FIG. 1 is a perspective view of a tongue depressor loaded with an active pharmaceutical ingredient according to an embodiment of the present disclosure. [Figure 5A] FIG. 2 is a perspective view of an adder constructed in accordance with one embodiment. [Figure 5B] FIG. 5B is a schematic diagram of a method of dosing using the dosing machine shown in FIG. 5A. [Figure 6] FIG. 2 is a schematic diagram of a control system in one embodiment. [Figure 7] FIG. 2 is a schematic front view of an adder incorporating a control system according to one embodiment. [Figure 8A] FIG. 11 is a schematic front view of an adder incorporating a control system according to another embodiment. [Figure 8B] FIG. 8B is a schematic top view of the adder shown in FIG. 8A with the adder head removed for illustrative purposes. [Figure 8C] FIG. 8C is another schematic top view of the adder shown in FIG. 8B incorporating a control system in yet another embodiment. [Figure 9] 1 is a plot showing stability zones in one embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0009] One or more different aspects may be described in this application. Moreover, for one or more of the aspects described herein, numerous alternative configurations may be described; it should be understood that these are presented for illustrative purposes only and in no way limit the scope of the aspects contained herein or the claims presented herein. One or more of the configurations may be broadly applicable to numerous aspects, as is readily apparent from the disclosure. In general, the configurations have been described in sufficient detail to enable one skilled in the art to practice one or more of the aspects, and it should be understood that other configurations may be utilized, and that structural, logical, software, electrical, and other changes may be made without departing from the scope of a particular aspect. Specific features of one or more of the aspects described herein may be described with reference to one or more specific aspects or figures that form a part of this disclosure, in which specific configurations of one or more of the aspects are shown by way of example. However, it should be understood that such features are not limited to use in the specific aspect or figures to which they are described. This disclosure is not a literal description of all configurations of one or more of the aspects, nor a list of one or more features of the aspects that must be present in all configurations.
[0010] The section headings provided in this patent application and the title of this patent application are for convenience only and are not to be construed as limiting the disclosure in any way.
[0011] Devices that are in communication with each other need not be in continuous communication with each other unless otherwise specified. In addition, devices that are in communication with each other may communicate directly or indirectly through one or more logical or physical communication means or intermediaries.
[0012] A description of an aspect in which several components are in communication with one another does not imply that all such components are required. Conversely, a variety of optional components may be described to illustrate a wide range of possible aspects and to more fully illustrate one or more aspects. Similarly, although process steps, method steps, algorithms, and the like may be described in a sequential order, such processes, methods, and algorithms may generally be configured to operate in alternative orders unless specifically stated otherwise to the contrary. In other words, any sequence or order of steps that may be described in this patent application does not, in and of itself, indicate a requirement that the steps be performed in that order. The steps of a described process may be performed in any practical order. Furthermore, some steps may be performed simultaneously, even though they are described or implied as occurring non-concurrently (e.g., because one step is described after the other). Furthermore, the illustration of a process by its depiction in a drawing does not imply that the illustrated process is exclusive of other variations and modifications thereto, nor does it imply that the illustrated process, or any of its steps, are required for one or more of the aspects, nor does it imply that the illustrated process is preferred. Also, although steps are generally described once per embodiment, this does not imply that they must occur once or that they may occur only once each time a process, method, or algorithm is performed or executed. Some steps may be omitted in some embodiments or occurrences, or some steps may be performed multiple times in a given embodiment or occurrence.
[0013] It will be readily apparent that where a single device or article is described herein, multiple devices or articles may be used in place of the single device or article. Similarly, where multiple devices or articles are described herein, it will be readily apparent that a single device or article may be used in place of the multiple devices or articles. In this regard, a description of a singular element herein applies with equal force to multiple singular elements and at least one of the singular elements. Thus, the terms "a", "an", and "the" used in connection with a singular apparatus or method step herein include multiple apparatuses or method steps, and at least one of the apparatuses or method steps. Conversely, a description of a plural element herein applies with equal force to the singular element, or at least one of the singular elements. Thus, a plurality of apparatuses or method steps described herein includes the singular forms "a", "an", "the", and "at least one".
[0014] The functionality or features of a device may alternatively be embodied by one or more other devices not explicitly described as having such functionality or features, and thus other aspects need not include the device itself.
[0015] Techniques and mechanisms described or referenced herein are sometimes described in the singular for clarity. However, it should be understood that a particular aspect may include multiple iterations of a technique or multiple instantiations of a mechanism unless otherwise specified. Process descriptions or blocks in the figures should be understood as representing modules, segments, or portions of code that include one or more executable instructions for performing specific logical functions or steps in the process. Alternative embodiments are within the scope of various aspects in which functions may be performed in different orders than those shown or described, including substantially simultaneously or in reverse order, depending on the functionality involved, for example, as will be appreciated by those skilled in the art.
[0016] As described below, methods and apparatus are provided for adding a desired dose of an active pharmaceutical ingredient (API) to a food or other substrate. In particular, as described in detail below, the addition system can include an adder having an addition head that delivers microdroplets containing the API to an underlying substrate, and an imaging system configured to image the microdroplets as they travel from the addition head to the substrate.
[0017] 1A-2, all of the above method steps and apparatus described herein, including the active-containing substrate, may be incorporated into or provided by any suitable dosing system 20. Although an example of the dosing system 20 is illustrated and described herein, it is recognized that, as noted above, numerous alternatives are available for dispensing a dose of a medicament active onto or into a desired substrate. In one example, the dosing system 20 is configured to deliver the active pharmaceutical ingredient 22 to a substrate 23, which may be configured as an edible product 24, thereby producing an active-containing substrate. When the substrate is an edible product, the active-containing substrate may be referred to as an active-containing edible product. As noted above, the edible product 24 may be any suitable food product. Additionally, as noted above, the active pharmaceutical ingredient may include at least one cannabinoid, at least one alternative drug or substance that provides a health benefit or recreational drug experience, or any desired alternative ingestible controlled substance as specified by law. It will be appreciated that the dosing system 20 may provide a cost-effective and efficient method for providing a product line of substrates having desired amounts and types of active pharmaceutical ingredients.
[0018] In some cases, it may be desirable to add one or more supplemental edible products to the prepared edible product 24 before or after the active pharmaceutical ingredient 22 is delivered to the edible product 24. Examples include adding icing to cookies or frosting to brownies or cakes. However, in these examples, the cookies and brownies may be fully cooked or otherwise prepared before adding the pharmaceutical ingredient. The system 20 may include up to one or more of a delivery station 28 configured to receive one or more edible products, an addition station 36 configured to deliver an approximate dosage of the active pharmaceutical ingredient (API) 22 to one or more edible products, a post-processing station 40, and a packaging station 42 that may be configured to package the edible product 24 carrying the approximate dosage of the active pharmaceutical ingredient 22. In some examples, the approximate dosage may be an exact dosage as described herein. Post-processing station 40 may be configured to at least one of: 1) dry out the solvent, for example if the API is delivered as a solution; 2) change, e.g., increase, the viscosity of the API; 3) further adhere the API to the substrate; 4) distribute the API along the substrate; 5) increase absorption or diffusion of the API into the substrate. Operation of the system may be controlled by any suitable controller, such as the Champion 3700 Digital Dispensing Benchtop System, available from Creative Automation Company, having offices in Sun Valley, Calif.
[0019] The terms "substantially," "approximately," "about," and words of similar import, when used in reference to an amount, volume, mass, weight, dose, size, shape, orientation, or other parameter, specifically include the stated parameter within plus or minus 20% of the stated parameter, including, for example, within plus or minus 5% of the stated parameter, including, for example, within plus or minus 10% of the stated parameter, including, for example, within plus or minus 1% of the stated parameter, along with ranges within plus or minus 2% of the stated parameter.
[0020] In the case where the at least one active pharmaceutical ingredient is delivered as an API-containing liquid 25, which may be a solution of the type described above, or a pure API, for example as an oil, the dosing system 20 may include a holding tank 26 configured to hold the liquid 25. Thus, the liquid 25 may be a pure cannabis extract in one example, but in other examples, the cannabis extract may be mixed or otherwise combined with one or more other substances, such as a solvent, as desired. In one example, the liquid is a solution having an approximate concentration of the cannabinoids or other active pharmaceutical ingredients 22 described above. The approximate concentration of the active pharmaceutical ingredient in the API-containing substance may be a known concentration as described above. Thus, the active pharmaceutical ingredient 22 may define the solute of the solution, and the solution may define any suitable solvent. In one example, the solvent may be an alcohol, such as ethanol or any alternative alcohol, as desired, or any other viscosity reducing agent, as desired. In one example, the liquid 25 may contain the active pharmaceutical ingredient in a concentration ranging from about 40% up to about 90%, such as from about 50% to about 70% by volume in solution with the solvent. It will be appreciated that the solvent may be removed substantially in its entirety during a subsequent drying step, e.g., the solvent may readily evaporate after being applied to the edible product 24. Nevertheless, it would be desirable for the solvent to be one that is safe for consumption in trace amounts.
[0021] Alternatively, the cannabinoid or other active API-containing liquid 25 may be a free-standing extract, meaning that it is not mixed with a carrier designed to be burned or otherwise vaporized. The extract may be purified, partially purified, or unpurified as desired. Such a free-standing extract may be in the form of a resin having a relatively high viscosity, which may prevent the extract from flowing freely enough to be easily delivered to the substrate 23. Thus, as described in more detail below, the dosing system 20 may include one or more heaters configured to increase the temperature of the extract, thereby reducing the viscosity of the API-containing liquid. Alternatively or additionally, an additive, such as alcohol, may be added to the liquid 25, which reduces the viscosity of the liquid. The alcohol is easily evaporated after the liquid 25 is applied to the substrate 23. It is recognized that an extract having a suitably low viscosity may be easily delivered to the substrate in any manner described herein. For example, it may be desirable to maintain the extract at a heated temperature while applying the extract to the substrate 23. The heating temperature may range from about 100°F to about 200°F, for example, from about 150°F to about 180°F. It is contemplated that the extract will have a sufficiently low viscosity at room temperature, but nevertheless, in some cases, it may be desirable to maintain the solution at the heating temperature. Since the approximate dose of at least one cannabinoid in the liquid 25 is known, the predetermined approximate volume of liquid 25 delivered from the holding tank 26 to the dosing station 36, and thus to the edible item 24, can contain approximately the predetermined desired approximate dose of pharmaceutical ingredient 22.
[0022] The delivery station 28 may be configured to receive a plurality of substrates 23, such as a plurality of edible products 24. Although the substrate is shown as an edible product 24, it is recognized that the substrate may be configured as any suitable alternative substrate as described above. In one embodiment, the dosing system 20 includes one or more support surfaces 30 of at least one support member 32, which are configured to receive and support a respective one or more edible products 24. The support surfaces 30 may be defined by respective predefined locations of the support members 32. The predefined locations may be defined by geometric markings. Alternatively or additionally, the predefined locations may be defined by pockets 34 defined by the support members 32. At least one or both of the support members 32 and the dosing station 36 may be movable to align the dosing station 36 with the edible products 24. The dosing station 36 may be configured to deliver an approximate volume of liquid 25 to one edible food product at a time, or may be configured to deliver multiple approximate volumes of liquid 25 to respective multiple edible food products simultaneously. Addition station 36 may be configured as an ultra-low volume liquid handling machine commercially available from Biofluidix, having offices in Freiburg, Germany.
[0023] In one embodiment, the support member 32 may be configured as any suitable delivery member, such as a conveyor 38 or other suitable support member designed to support and transport the edible product to be operatively aligned with the application station 36. The conveyor 38 may be correspondingly movable to transport the edible product 24 from the delivery station 28 to the application station 36. Alternatively, the support surface 30 may be stationary and the application station 36, including applicators that may be configured as one or more application heads as described below, may be movable to be aligned with the substrate 23. Further alternatively, both the support surface 30 and the application station may be movable to align the application head with the substrate 23. It may thus be stated that at least one of the support surface 30 and the application station 36 may be movable relative to the other of the support surface 30 and the application station 36 to align the substrate 23 with the application head of the application station 36.
[0024] Further alternatively, it will be appreciated that the addition system 20 may be configured for self-service, whereby a user places the substrate on the support surface 30 at the addition station 36. Alternatively, a user may place the substrate 23 on the support surface 30 and manually move the substrate 23, for example along the support surface 30, to the addition station 36. In this embodiment, the support surface 30 may be a stationary support surface. Additionally, the addition station may be stationary.
[0025] After the active pharmaceutical ingredient is delivered from the addition station 36 to the substrate 23, the active-containing substrate 23 may be moved from the addition station 36 to a post-treatment station 40. The active-containing substrate 23 may be moved from the addition station 36 to a post-treatment station 40 using the support surface 30 or any suitable alternative device. In this regard, the post-treatment station 40 may be positioned in-line with the addition station 36 along the support surface 30 in some embodiments. Alternatively, the post-treatment station 40 may be offline relative to the support surface 30. Thus, the active-containing substrate may remain at the post-treatment station 40 for a desired amount of time until the active-containing substrate is suitable for packaging. At this point, the active-containing substrate may be moved from the post-treatment station 40 to a packaging station 42. The support surface 30 or any suitable alternative device may move the active-containing substrate from the post-treatment station to the packaging station 42. In this regard, the post-treatment station 40 may be positioned in-line with the addition station 36 along the support surface 30 or may be offline relative to the support surface 30.
[0026] Once the edible product 24 is aligned with the dosing station 36, the dosing station 36 is configured to deliver a predetermined approximate volume of an active pharmaceutical ingredient, such as at least one cannabinoid, to the edible product. In some examples, the active pharmaceutical ingredient may be presented as a liquid 25. Since the concentration of the active pharmaceutical ingredient in the liquid 25 is known and the desired dosage of the active pharmaceutical ingredient to be delivered to the substrate 23 is known, an approximate volume of the liquid 25 to be delivered to the substrate 23 may be determined. In some examples, an electrostatic force may be generated that drives the active pharmaceutical ingredient into the substrate 23, thereby causing the active pharmaceutical ingredient and the substrate to be oppositely charged. For example, the substrate 23 may be given a negative charge and a positive charge may be added to the liquid or powder to be delivered, thereby creating an electrostatic charge.
[0027] It will be appreciated that in other examples, the active pharmaceutical ingredient may be delivered to the substrate 23 as a powder. For example, the liquid 25 containing at least one cannabinoid may be an initial form of a resin that can be dried and crystallized. The resulting crystals can be ground into a powder having a desired dosage of the active pharmaceutical ingredient. Since the density of the active pharmaceutical ingredient in the powder is known and the desired dosage of the active pharmaceutical ingredient to be delivered to the substrate 23 is known, an approximate mass of powder to be delivered to the substrate 23 by the dosing station 36 can be determined.
[0028] The dosing station 36 may include at least one applicator, e.g., a plurality of applicators, of the type described above. Each applicator may define a dosing head 46 configured to dispense a respective approximation of the approximation volume of the liquid 25 delivered from the holding tank 26. Thus, the dosing station 36 may include at least one dosing head 46, e.g., a plurality of dosing heads 46. The dosing station 36, particularly the applicators, and thus the dosing heads 46, are in fluid communication with the holding tank 26. Thus, the dosing heads 46 are configured to receive respective amounts of the volume of the liquid 25 delivered from the holding tank 26 and dispense the respective amounts to the edible product 24. The respective amounts dispensed by the dosing heads 46 cumulatively define the approximation volume of the liquid 25 received from the holding tank 26.
[0029] As will be described, the dosing head 46 can be configured to deliver a precise amount of the volume of the liquid 25 to the edible product 24. In some embodiments, the precise amount can be a minute amount that is applied to the edible product 24 in the form of droplets that can be sized as microdroplets, as will be described in more detail below. Thus, the edible product 24 can receive a predictable dose of the active pharmaceutical ingredient. Furthermore, the dose of the active pharmaceutical ingredient can be applied at a specific location of the edible product as desired. For example, in certain embodiments, it may be desirable to deliver the active pharmaceutical ingredient such that the active pharmaceutical ingredient is substantially uniformly distributed on or in the edible product 24. As a result, for example, if the edible product is a large baked food, consuming various areas of the edible product with equal volumes will result in the ingestion of substantially the same amount of the active pharmaceutical ingredient. One non-limiting example of a large baked food can be a brownie. Furthermore, if the edible product 24 is a bite-sized food product that is a product of batch ingredients that have been mixed and / or cooked and then singulated, consumption of various bite-sized food products having equal volumes will result in the ingestion of substantially the same amount of the active pharmaceutical ingredient. One non-limiting example of such a bite-sized food product may be a gummy candy. Bite-sized food products are those designed to be consumed completely in one bite, such as dried fruits and nuts and gummy candy. In one example, the dosing head 46 may be defined by a True Volume™ Piston Positive Displacement Pump available from Creative Automation Company having a place of business in Sun Valley, California. In another example, the dosing head 46 may be defined by a Pipetman M P10M device available from Gilson Inc. having a place of business in Middleton, Wisconsin.
[0030] 2, the dosing station 36 can include an injection reservoir 49 disposed between the holding tank 26 and the dosing head 46. The dosing station 36 can include a first conduit 51 extending from the holding tank 26 to the reservoir 49 and a second conduit 53 extending from the reservoir 49 toward the dosing head 46. Thus, the reservoir 49 can receive the volume of liquid 25 from the holding tank 26. The dosing station 36 can further include a second conduit 53 extending from the reservoir 49. The second conduit 53 can extend to a manifold 55. Thus, the reservoir 49 can deliver the volume of liquid 25 to the manifold 55 under a pressure differential provided by the pump, which can distribute the volume of liquid 25 to the dosing head 46. In this regard, it should be understood that the second conduit 53 is in fluid communication with the dosing head 46. The pump can be a positive pump that defines a positive pressure differential. The holding tank 25 can be under a positive pressure to provide a positive force that urges the liquid 25 from the holding tank 26 towards the dosing head 46. Alternatively, the holding tank 25 can be under a negative pressure to draw the liquid 25 from the holding tank 26 towards the dosing head 46. In other embodiments, the dosing system 20 can include multiple pumps, each configured to provide a respective pressure differential to a respective one or more of the dosing heads 46.
[0031] Each pump defines a piston movable within a cylinder along a stroke length at a stroke speed to eject a predetermined precise volume of liquid 25 as successive microdroplets. The liquid 25 has a concentration of API such that the piston moves within the cylinder along the stroke length at a stroke speed to eject a predetermined precise amount of API as successive microdroplets. If the stroke length and / or stroke speed are decreased, the size of the resulting microdroplets may be reduced. Conversely, if the stroke length and / or stroke speed are increased, the size of the resulting microdroplets may be increased. In one embodiment, the multiple pumps may include respective pistons movable within corresponding cylinders along respective stroke lengths to eject a predetermined precise volume of liquid 25 as successive microdroplets. In this regard, the stroke length of the piston that delivers the liquid 25 to the first at least one dosing head 46 may be different from the stroke length of the piston that delivers the liquid 25 to the second at least one dosing head 46. Alternatively, the pump can include a resilient micropipe having an inner diameter that is partially squeezed by a piezo stack actuator to drive liquid 25 from the dispensing head 46 .
[0032] In some examples, the different dosing heads 46 may be configured to deliver different amounts of respective volumes of liquid 25 to the edible product 24 (see FIG. 1). Additionally, the liquid 25 delivered by the first at least one dosing head 46 may contain a different active pharmaceutical agent than the liquid 25 delivered by the second at least one dosing head 46. Additionally, the dosing system 20 may be configured to deliver any number of API-containing liquids 25, each containing a different pharmaceutical agent, to each of the at least one dosing heads 46. Thus, the dosing heads 46 may be combined to deliver active pharmaceutical agents from different liquid extracts in different amounts onto a common substrate 23. Alternatively or additionally, the different liquids may have different concentrations of their respective active pharmaceutical agents. Thus, the dosing system 20 may include any number of holding tanks 26 as desired, each tank containing a different liquid extract containing at least one different pharmacoactive ingredient. The different liquid extracts may be delivered to different ones of the dosing heads 46. Thus, the different dosing heads may be configured to deliver different cannabinoids to the substrate.
[0033] As an example, a first group of dosing heads 46 may be configured to deliver microdroplets having a dosage of a first active pharmaceutical agent, and at least one dosing head 46 of a second group, e.g., a plurality of dosing heads 46, may be configured to deliver a second microdroplet having a dosage of a second active pharmaceutical agent, the second active pharmaceutical agent being different from the first active pharmaceutical agent. For example, the first active pharmaceutical agent may be THC and the second active pharmaceutical agent may be CBD. Furthermore, the first active pharmaceutical agent may be delivered at a predetermined approximate dosage amount different from the second active pharmaceutical agent. Furthermore, the tank containing the first active pharmaceutical agent may be maintained at a different temperature than the second tank. Thus, the viscosity of each of the API-containing liquids 25 may be individually controlled. In addition, the temperature of all of the one or more of the respective conduits 51, 53 and at each dosing head 46 may be different to individually control the viscosity of each liquid extract as it travels from the respective tank to the respective one or more dosing heads 46. In other examples, a first group of dosing heads 46 can be configured to deliver microdroplets having a first dose of an active pharmaceutical agent, and a second group of dosing heads 46 can be configured to deliver second microdroplets having a second dose of an active pharmaceutical agent, which in some examples can be less than the first dose.
[0034] The dosing system 20 can include any suitable feedback mechanism to provide an indication that the at least one dosing head 46 has delivered the at least one active pharmaceutical ingredient to the substrate 23. The feedback mechanism can be a closed feedback loop in some embodiments. For example, a pressure sensor can be disposed in the conduit 53 to measure the back pressure in the conduit 53. For example, a decrease in back pressure can indicate that each of the at least one dosing heads 46 has delivered each of the at least one active pharmaceutical ingredient to the substrate 23. Alternatively, the dosing system 20 can include a load cell that determines that the substrate 23 is aligned with the dosing head 46 by sensing weight. Still alternatively, the dosing system 20 can include a visual recognition system that includes a visual sensor to visually identify that the substrate 23 is aligned with the dosing head 46. Thus, it is understood that in some embodiments, the substrate 23 can be positioned anywhere on the support surface, not necessarily at a predetermined location on the support surface.
[0035] Additionally, the addition system 20 can include a camera designed to measure a quantification of the microdroplets delivered from the addition head 46. For example, the camera can measure the cross-sectional dimension of the microdroplets as they move from the addition head 46 to the substrate 23. It is recognized that the microdroplets may be elongated as they move from the addition head. However, the surface tension of the microdroplets may cause the microdroplets to become more spherical as they move from the addition head 46 to the substrate. Thus, in one embodiment, the cross-sectional dimension may be a maximum cross-sectional dimension that approximates the diameter of a sphere, and an estimate of the volume of the microdroplets may be calculated as desired. However, the cross-sectional dimension may be any suitable alternative cross-sectional dimension that relates to the volume of the microdroplets. The cross-sectional dimensions of the microdroplets or the calculated volume estimates may be compared to one another to ensure repeatability of the volume of the microdroplets being delivered to the substrate 23 or to verify a desired variation in the volume of the microdroplets. The cross-sectional dimensions or the calculated estimates may then be integrated into a feedback loop to ensure proper operation of the addition system 20. In one embodiment, the camera may be a SmartDrop System available from Biofluidix, having offices in Freiburg, Germany.
[0036] As mentioned above, the dosing system 20 can be configured to deliver heat to the liquid 25 either in one or more of the conduits and / or in the dosing head 46 prior to or during dispensing of the API-containing liquid to the substrate 23. The heat can be sufficient to reduce the viscosity of the API-containing liquid 25. In some examples, for example, if the API-containing liquid 25 includes a solvent, the step of delivering heat to the liquid 25 can evaporate the solvent such that a pure API having a sufficiently low viscosity is dispensed from the dosing head 46. Thus, in one example, the API-containing liquid 25 can include an API and a solvent and can travel from the holding tank 26 to the dosing head 46. The API-containing liquid 25 can be heated between the holding tank 26 and the dosing head 46 to reduce the viscosity of the liquid 25 and, in some cases, evaporate some or all of the solvent. Alternatively or additionally, the API-containing liquid 25 can be heated at the dosing head 46 to reduce the viscosity of the liquid 25 and, in some cases, evaporate some or all of the solvent. In one embodiment, the dosing system 20 can include at least one heater that delivers heat from one or more of the first conduit 51, the second conduit 53, the injection reservoir 49, the manifold 55, and the dosing head 46 up to all of them to reduce the viscosity of the API-containing liquid and, in some cases, evaporate the solvent. In one embodiment, the liquid 25 can be maintained at a temperature ranging from about 100°F to about 200°F, such as from about 140°F to about 200°F, in one embodiment, from about 150°F to about 180°F. Alternatively, in some embodiments, such as when the liquid 25 is a solution, the liquid 25 can be maintained at room temperature.
[0037] Although the dosing head 46 may be configured to deliver a liquid 25 containing at least one active pharmaceutical ingredient to the substrate 23 in one embodiment, the dosing head 46 may instead be configured to deliver at least one active pharmaceutical ingredient in solid or powder form to the substrate 23 in the manner described herein with respect to the liquid 25. Thus, the above examples of applying an active pharmaceutical ingredient in the form of a liquid may apply with equal force to a powder containing at least one active pharmaceutical ingredient, unless otherwise indicated. Each dosing head 46 may be configured to deliver microdroplets of the API, as described above. It should therefore be understood that the powder may be delivered to the substrate 23 as a micro-amount. The powder may be stored in the holding tank 26 and may be led to the dosing head 46 through the first conduit 51 and the second conduit 53, either directly or through the manifold 55. It may therefore be said that a quantity of API-containing material may be applied to the substrate 23. The API-containing material may be in the form of a powder or liquid. Thus, the API-containing material may contain a desired concentration of the active pharmaceutical ingredient, as described above. In other embodiments, the API-containing material may contain only active pharmaceutical ingredients.
[0038] Additionally, each of the dosing heads 46 may be configured to dispense the API-containing liquid 25 received from the holding tank 26, although it will be appreciated that the API-containing liquid 25 may be delivered using other methods. For example, the dosing system 20 may include a first holding tank containing the API in liquid or solid form and a second holding tank containing the solvent. The API and the solvent may be mixed in the dosing station 36. For example, the API and the solvent may be mixed in the dosing head 46. In one example, the dosing head may include a first chamber that receives the API and a second chamber that receives the solvent. The API and the solvent may be mixed in the dosing head 46 to generate a solution having a predetermined concentration of the API. The solution generated in the dosing head 46 may then be dispensed as one or more microdroplets in the manner described herein. In some examples, this concentration may be varied in the dosing head 46. That is, the respective proportions of API and solvent mixed in the dosing head 46 may be altered. Additionally, the API or solution may be mixed with at least one other ingestible conditioning agent configured to modify at least one of the flavor, one or more mechanical properties, or one or more aesthetic properties of the cannabis or hemp material. Mixing may occur within the dosing head 46 or at any other location as desired. For example, in some embodiments, at least one other edible product may be mixed into the liquid 25 in the holding tank 26.
[0039] 1A-2B, in one embodiment, the addition heads 46 may be arranged in an array 48 including at least one row 50 of addition heads 46. The addition heads 46 in each row 50 may be spaced substantially equidistantly apart along their respective rows 50. Alternatively, the addition heads 46 may be variably spaced apart along their respective rows 50. The array 48 may further include a plurality of columns 52 that space the rows 50 apart from one another. Each of the addition heads 46 in the array 48 may deliver successive microdroplets along a respective flow path from the addition head to an underlying substrate or substrates. The addition heads 46 may be spaced equidistantly apart along their respective columns 52. Alternatively, the addition heads 46 may be variably spaced apart along their respective columns 52. In one embodiment, all of the addition heads 46 may be configured to deliver the same at least one active pharmaceutical ingredient. Alternatively, different groups of addition heads 46 may be configured to deliver respective different active pharmaceutical ingredients, as described above. Each group can include at least one application head 46 and up to multiple application heads 46. Each group can be defined by one or more of the respective rows 50. Alternatively, each group can be defined by one of the respective columns.
[0040] 1A-3, the addition heads 46 may be aligned with different respective locations of the addition zone 54 of the edible product 24. Thus, the addition heads 46 may be positioned to deliver their respective amounts of the volume of the liquid 25 to the different respective locations of the addition zone 54. Additionally, the addition system 20 may be configured to deactivate selected addition heads 46 that are not aligned with the addition zone 54 and therefore do not receive their respective portions of the volume of the liquid 25, and activate selected addition heads 46 that are aligned with the addition zone 54 and therefore receive their respective portions of the volume of the liquid 25. In some embodiments, the addition system 20 may include a sensor that identifies the addition zone 54 of the edible product 24. The sensor may be a camera, a weight sensor that measures the weight of the substrate 23 on the support surface and determines the addition zone based on the weight and / or size, or any suitable alternative sensor. The addition zone 54 may be at least partially defined by the perimeter 56 of the edible product 24. For example, the addition zone 54 may be defined in its entirety by the perimeter 56 of the edible product 24. Thus, the entire outer surface of the edible product 24 can define the addition zone 54. In some examples, the addition zone 54 can be located entirely within the perimeter 56. For example, the addition zone 54 can be greater than half, such as greater than 75%, of the footprint defined by the perimeter. In any event, it can be said that the addition zone 54 can be substantially a predetermined location relative to the perimeter 56 of the edible product 24. Thus, the addition zone 54 can be consistent among a number of different sizes of edible products 24, such as cookies or brownies, which can have similar, but not identical, sizes and shapes.
[0041] The addition heads 46 may be spaced apart from one another as desired to deliver a desired distribution of the active pharmaceutical ingredient into the addition zone 54 of the edible product 24. Alternatively, one or more of the addition heads 46 may be movable to deliver the active pharmaceutical ingredient to multiple locations of the edible product 24. In one embodiment, the addition heads 46 are configured to deliver a substantially uniform distribution of the volume of liquid 25 into the addition zone 54 of the edible product 24. For example, each amount of the volume of suspension dispensed by each of the addition heads 46, or each of the plurality of addition heads, may be substantially equal to each amount of suspension dispensed by the other addition heads 46 or the other plurality of addition heads 46.
[0042] In another embodiment, the dosing system 20 can divide the dosing zone 54 into a plurality of subzones. Each subzone can be configured to receive a different at least one active pharmaceutical ingredient. Thus, at least one dosing head 46 of the first group can deliver a first at least one active pharmaceutical ingredient to a first subzone of the subzones, and at least one dosing head 46 of the second group can deliver a second at least one active pharmaceutical ingredient different from the first at least one active pharmaceutical ingredient to a second subzone of the subzones. Alternatively or additionally, at least one dosing head 46 of the first group can be configured to deliver a first dosage of the first at least one active pharmaceutical ingredient, and at least one dosing head 46 of the second group can be configured to deliver a second dosage of the second at least one active pharmaceutical ingredient different from the first dosage. In yet another embodiment, at least one dosing head 46 of the first and second groups can be configured to deliver different dosages of the same at least one active pharmaceutical ingredient. The active pharmaceutical ingredient may be substantially uniformly distributed in each of the subzones.
[0043] In some examples, at least one dosing head 46, such as a plurality of dosing heads 46, can be movable along the substrate 23 to deliver each of the at least one active pharmaceutical ingredient at different locations of the edible product 24. Additionally, the dosing heads 46 can be configured to deliver different active pharmaceutical ingredients to the substrate 23. For example, the dosing heads 46 can be configured to deliver different combinations of liquids and / or powders. In one example, the dosing head 46 can deliver a first liquid or powder containing a first active pharmaceutical ingredient to the substrate 23. The dosing head 46 can then deliver a second active pharmaceutical ingredient, different from the first active pharmaceutical ingredient, to the substrate 23. The dosing head 46 can then deliver a third active pharmaceutical ingredient, different from each of the first and second active pharmaceutical ingredients, and so on, to the substrate 23 until all desired active pharmaceutical ingredients have been delivered to the substrate 23.
[0044] When the dosing heads 46 are arranged as a group of dosing heads 46 each delivering a respective different at least one active pharmaceutical ingredient, the different active pharmaceutical ingredients can be delivered to respective different locations of the substrate 20. For example, the dosing heads 46 can remain stationary relative to the substrate 23 as the active pharmaceutical ingredients are delivered to the substrate 23. Alternatively, the dosing heads 46 can be movable along the substrate 23, and a combination of active pharmaceutical ingredients as delivered by at least one dosing head 46 of different groups can be delivered to the same respective location of the substrate 20. The heads 46 can be movable such that the dosing heads 46 can deliver respective active pharmaceutical ingredients to respective locations of the substrate 23 that are different from the other dosing heads. The active pharmaceutical ingredients at the different respective locations can be substantially uniformly distributed in at least one direction along the substrate 23. For example, the active pharmaceutical ingredients at the different locations can be substantially uniformly distributed in two perpendicular directions along the substrate 23.
[0045] The substrate 23 includes an outer surface defining an inner surface 60 facing the support surface 30 and an outer surface 58 opposite the inner surface 60. The dosing head can deliver the active pharmaceutical ingredient to the outer surface 58 of the substrate 23. The edible product 24 defines a thickness extending from the inner surface 60 to the outer surface 58. The delivered volume of the active pharmaceutical ingredient can remain substantially on the outer surface 58. Delivering this volume of liquid to the outer surface 58 can expose the liquid to oral receptors, thereby increasing the rate of uptake of the active pharmaceutical ingredient. Alternatively or additionally, the delivered volume of liquid 25 can permeate the outer surface 58 to soak into at least a volume of the thickness of the edible product extending from the outer surface 58 to the opposite inner surface 60. Alternatively, the active pharmaceutical ingredient can be infused into the substrate 23 between the inner surface 60 and the outer surface 58. For example, at least 20% of the active pharmaceutical ingredient can be located in the central 75% of the thickness. The central 75% of the thickness can be spaced equidistant from each of the inner surface 60 and the outer surface 58. For example, at least 20% of the active pharmaceutical ingredient can be disposed in the central 50% of the thickness. The central 50% of the thickness can be spaced equidistant from each of the inner surface 60 and the outer surface 58. In some examples, the distribution along the outer surface of the substrate 23 can be different than the distribution along the thickness of the substrate 23 from the outer surface to the inner surface.
[0046] In one embodiment, the dosing head 46 can be configured to deliver respective amounts of the active pharmaceutical ingredient in the form of microdroplets 62 to respective locations on the outer surface 58 of the edible product 24. The microdroplets 62 can have any suitable size and shape as desired. In one embodiment, the microdroplets 62 can include minute amounts of the active pharmaceutical ingredient. For example, the microdroplets 62 can define a maximum cross-sectional dimension along a horizontal direction that is within a range of about 5 millionths of an inch to about 100 thousandths of an inch, for example, when printed. For example, the range can be about 5 thousandths of an inch to about 50 thousandths of an inch. In one embodiment, the maximum cross-sectional dimension along a selected direction can be within a range of about 20 thousandths of an inch to about 40 thousandths of an inch. The dosing head 46 is spaced from the edible product 24 along a direction of movement of the active pharmaceutical ingredient from the dosing head 46 to the edible product 24. Thus, the active pharmaceutical ingredient is delivered to the substrate along this direction of movement. The selected direction may be substantially perpendicular to the direction of movement. In one embodiment, the dosing head 46 is spaced above the edible product 24 along a vertical direction. Thus, the selected direction may be a substantially horizontal direction. For example, the dosing head 46 may be spaced any suitable distance from the edible product 24 when delivering the active pharmaceutical ingredient to the edible product 24, such as from about 2 mm to about 25 mm. As shown in FIG. 2B, at least some, up to all of the microdroplets 62 may be substantially spherical. Alternatively or additionally, as shown in FIG. 2C, at least some, up to all of the microdroplets 62 may be elongated, e.g., substantially teardrop-shaped, or alternatively shaped as desired.
[0047] In one embodiment, the microdroplets 62 are delivered from the dosing head 46 to the respective locations of the edible product 24 under any suitable force, such as gravity, electrostatic force, etc. In another embodiment, the microdroplets 62 are delivered from the dosing head 46 to the respective locations of the edible product 24 under positive pressure. In this regard, the dosing station 36 can control whether the microdroplets 62 remain on the outer surface 58 of the edible product 24 and whether the microdroplets 62 penetrate the thickness of the edible product 24 through the outer surface 58 in the manner described above. In yet another embodiment, one or more of the dosing heads 46 can be coupled to respective needles that can be driven into the edible product 24 to deliver respective amounts of volumes of the liquid 25 to locations between the outer surface 58 and the inner surface 60 within the edible product 24. In some cases, the needles can be heated at a suitable temperature to soften or melt locations of the substrate contacted by the needles to aid in injection of the needles into the substrate. The heated needles can also maintain a desired viscosity of at least one active pharmaceutical ingredient as the active pharmaceutical ingredient is being delivered through the needles into the substrate. Whether the active pharmaceutical ingredient is delivered to the edible product 24 as microdroplets or as an injectable, the active pharmaceutical ingredient can be delivered to the edible product in minute amounts.
[0048] As mentioned above, the dosing system 20 can include a post-processing station 40 configured to process the edible product 24 after the liquid 25 is delivered thereto. The post-processing station 40 can be configured to dry the solvent, for example, when the API is delivered as a solution. In this regard, the post-processing station 40 can include any suitable drying member, such as a plurality of drying heads 70 or at least one drying head 70 configured to deliver a desiccant to respective locations of the edible product 24 to dry the liquid 25. It is understood that as the liquid 25 dries, the solvent of the delivered volume of liquid 25 carrying the active pharmaceutical ingredient can also dry and evaporate, leaving the active pharmaceutical ingredient on the substrate 23. In this regard, the drying heads 70 can be arranged in an array having the same number of rows and columns as the array of the dosing heads 46. Furthermore, the relative position of the drying heads 70 with respect to the other drying heads 70 can be the same as the relative position of the dosing heads 46 with respect to the other dosing heads 46. Thus, the drying head 70 can be aligned with the active pharmaceutical ingredient delivered to the edible product 24 by the addition head 46 .
[0049] The desiccant may be configured as any suitable light, including ultraviolet, laser, infrared, and the like. Alternatively, the desiccant may be a forced gas delivered to the exterior surface of the edible product 24. The forced gas may be any suitable alternative gas, such as air, nitrogen, or an inert gas. The forced gas may be heated and may have a temperature ranging, for example, from about 100°F to about 250°F. Alternatively, the forced gas may be substantially unheated and thus at ambient temperature. Alternatively, the forced gas may be cooled and thus at a temperature below ambient temperature. In this regard, the cooled forced gas may freeze the cannabinoids on the surface of the substrate or slow the evaporation of the solvent so that the cannabis-containing solution penetrates further into the thickness of the substrate 23. Alternatively, the post-treatment station 40 may expose the loaded substrate to ambient air or a controlled environment to dry the volume of liquid 25. It is recognized that the desiccant applied to the API may increase the viscosity of the API. The post-treatment station can further adhere the API to the substrate 23. For example, by increasing the viscosity, the API can be further adhered to the substrate 23. Additionally, applying forced air to the substrate 23 can disperse the API along the substrate as it moves along the outer surface of the substrate 23, thereby facilitating absorption of the API into the substrate 23. For example, it is recognized that the API can be saturated in the portion of the substrate 23 that is beneath the delivered microdroplets. Then, by moving the API along the outer surface of the substrate 23, the API can be absorbed into the substrate 23 at locations of the substrate 23 that are not saturated with the API. The post-treatment station 40 can further solidify the API on or in the substrate 23. In some examples, the API can crystallize on or in the substrate 23. Alternatively, the API can remain as an oil on or in the substrate 23. If the at least one cannabinoid is applied as a powder, the post-treatment step can apply heat to the powder, thereby liquefying the at least one cannabinoid on the substrate 23.The liquefied powder may then be cooled, causing the liquid to solidify, crystallize, or otherwise be deposited on or in the substrate 23.
[0050] It is understood that energy can be applied to the substrate 23 to improve diffusion or absorption of the API into the substrate 23. For example, when heat is applied to the surface of certain substrates 23, particularly certain edible products, such as chocolates, baked goods, gummy candies, lollipops, etc., the temperature of the surface of the edible product increases to a level at which the edible product melts, releases moisture, or otherwise assumes a form configured to encapsulate the API. The temperature can be increased, for example, by directing at least one of heated forced air and light at the surface.
[0051] Once the substrate 23 has been post-processed, the active-containing edible product 24 may be transferred from the post-processing station 40 to a packaging station 42. At the packaging station 42, the dry edible products 24 may be individually packaged in any suitable package 73. Alternatively or additionally, multiple active-containing edible products 24 may be packaged in a common package. The active-containing edible product 24 may include a cooked edible product and a dose of an active pharmaceutical ingredient carried by the cooked edible product in an application zone of the cooked edible product. The dose of the active pharmaceutical ingredient may be substantially uniformly distributed in the application zone. Because the edible product is fully cooked prior to adding the active pharmaceutical ingredient, there is no need to cook the active pharmaceutical ingredient after it is added.
[0052] In some examples, the edible product 24 may be configured as a plurality of nuts 37 (FIG. 4A) and / or fruits 39 (FIG. 4B), and / or a mixture of dried fruits and nuts, and possibly other additional food products. It is understood that the API is not visible in FIGS. 4A-4E due to the nature of the figures. The active pharmaceutical ingredient may be applied to the nuts and fruits in any suitable manner as disclosed herein. In some examples, the nuts are cooked, e.g., roasted. In other examples, the nuts may be raw. In some cases, the nuts or fruits may be prepared with salt, sugar, honey, or any suitable alternative ingredients. This may allow the nuts to be sweetened. In some examples, the fruit may be fresh fruit. In other examples, the fruit may be dried. In still other examples, the fruit may be sweetened. It is understood that the fruits and nuts may have a relatively low surface area and volume. Thus, variability in the dose of active pharmaceutical ingredient applied to the fruits and nuts may have a significant effect on the ratio of active pharmaceutical ingredient per volume of the edible product when compared to edible products having a larger surface area and volume.
[0053] Thus, it may be particularly advantageous to precisely control the dose of active pharmaceutical ingredient applied to the fruits and nuts. The active pharmaceutical ingredient may be applied to the fruits and nuts in a minute amount in the manner described above, thereby allowing precise control of the dose of active pharmaceutical ingredient applied to the fruits and nuts. It is recognized that microdroplets having respective volumes ranging from about 5 nanoliters to about 20 microliters may be delivered to individual fruits or nuts, depending on the size of the fruit or nut. Thus, each fruit or nut may contain an amount or dose of API ranging from about 2.5 micrograms to about 20 milligrams. Thus, each microdroplet may contain a minute amount of API ranging from about 0.5 micrograms to about 1 milligram. Of course, it is recognized that the dose of API per dried fruit or nut may vary as desired. For example, other amounts of microdroplets may be delivered to the fruits and nuts, depending, for example, on the size of the fruit and nut, the size of the microdroplets, and the concentration of the API in the microdroplets. The minute amount of API in the microdroplets allows the dose of API delivered to the substrate to be precisely controlled as described above. Additionally, the dosage of API per dried fruit or nut can be precisely controlled, even for multiple servings of dried fruit and / or nuts. For larger edible products such as baked foods41 (see Figure 4C), microdroplets can be applied in the range of about 5 nanoliters to about 20 microliters across the entire surface, greatly increasing the total API delivered to the substrate up to 100 milligrams or more.
[0054] It should be appreciated that several advantages may be achieved using the dosing system 20. In one embodiment, the substrate 23 may include multiple active pharmaceutical ingredients, thereby eliminating the traditional need to consume multiple medicaments, each having a single active pharmaceutical ingredient. Additionally, minute amounts of active pharmaceutical ingredients may be applied to the substrate. Thus, the dose of at least one active pharmaceutical ingredient carried by the substrate may be better controlled relative to traditional application processes. Additionally, the at least one active pharmaceutical ingredient may be substantially uniformly distributed along the dosing zone. Additionally, individual dosing of the active pharmaceutical ingredients on the substrate may allow for the use of locally manufactured active pharmaceutical ingredients that are applied after the substrate is prepared, thereby avoiding the need to transport the applied active pharmaceutical ingredients across jurisdictional lines, which may be illegal or subject to additional taxes in some jurisdictions. Additionally, dosing the substrate after the substrate has crossed jurisdictional lines may reduce or eliminate degradation of the active pharmaceutical ingredients during transport across jurisdictional lines, which may sometimes include long distance transport. In some embodiments, a dye may be used with the active pharmaceutical ingredient as desired to verify that the active pharmaceutical ingredient has been delivered to the substrate.
[0055] 5A-5B, it is recognized that in some embodiments, the dosing system 20 described above may be configured as a single integrated, separate dosing machine 72. The dosing machine 74 may include the conveyor 38, the holding tank 26, the delivery station 28, the dosing station 36, the post-processing station 40, and the packaging station 42. The dosing machine 74 may further include a support structure 76 that supports the conveyor 38, the holding tank 26, the delivery station 28, the dosing station 36, the post-processing station 40, and the packaging station 42. Thus, the conveyor 38, the holding tank 26, the delivery station 28, the dosing station 36, the post-processing station 40, and the packaging station 42 may be said to be integrated into a single, separate dosing machine and supported by the common support structure 76. As will be further described in more detail below, the dosing machine 72 may further include a camera that measures the maximum cross-sectional dimension of the microdroplets. Additionally, the dosing system 20 and the dosing machine 74 may include a washer configured to remove loose particulates from the substrate 23 prior to delivering the API to the substrate 23. For example, in the case of salted nuts, the loose salt can be removed from the nuts while the salt that has a strong adhesion to the nuts remains. In one embodiment, the washer can be configured to deliver forced air to the substrate to remove loose debris from the substrate. Thus, when the API is delivered to the substrate, the API can have a strong adhesion to the substrate 23. In some embodiments, the forced air can be heated to increase the temperature of the substrate to improve the absorption or diffusion of the API into the substrate in the manner described herein.
[0056] The delivery station 28 may include a hopper 76 or other storage member that houses one or more of the substrates 23. The delivery station 28 may further include a delivery member 78 configured to receive the substrates from the hopper 76 and deliver the substrates 23 from the hopper 76 to the addition station 36. For example, the delivery member 78 may transport the substrates 23 from the hopper 76 to the addition station 36 and further to a third location aligned with the delivery location where the added substrate is delivered to the conveyor 38. The delivery member 78 may include and define any suitable material that may have at least one elongated groove 80 or other suitable structure that directs the substrates 23 along a respective path 81 from the hopper 76 to the addition station 36. For example, the delivery member 78 may include a plurality of grooves 80 that define a plurality of paths 81 from the hopper 76 to the respective addition stations 36. Alternatively, the plurality of delivery members 78 may define respective grooves 80 that extend along respective paths from the hopper 76 to the respective addition stations 36.
[0057] In one embodiment, the delivery member 78 can be tilted downward along a direction from a first location aligned with the hopper 76 to a second location aligned with the addition station 36, and then to a third location aligned with the delivery location where the added substrate is delivered to the conveyor 38. Additionally, the delivery member 78 can be configured to vibrate, rock, or otherwise move the substrate 23 along the delivery member 78 from the first location to the second location, and from the second location to the third location. Alternatively, the delivery member 78 can be configured as a conveyor to move the substrate 23 from the first location to the second location, and from the second location to the third location. Alternatively, as described above, a user can manually move the substrate 23 along the delivery member 78 or otherwise move the substrate 23 to a position aligned with the addition station 36.
[0058] In operation, the substrates 23 are loaded into the hopper 76. The substrates 23 are then delivered from the hopper 76 to a first location on the delivery member 78. This delivery can be under gravity or any suitable alternative structure and method. In particular, the substrates 23 can be delivered to the delivery member 78 to be arranged along the respective paths 81. The substrates 23 can be individualized and arranged as a single file on the respective delivery member 78, and thus along the respective paths 81. Alternatively, a group of substrates 23 may be arranged on one or more of the delivery members 78. The substrates 23 moving along the respective paths 81 can define the same type of substrate, such as fruits or nuts, or baked foods, etc. Alternatively, substrates 23 of different types can move along the respective paths 81. For example, the substrates 23 moving along one path can include dried fruits. The substrates 23 moving along another path or the same path can include raw or roasted nuts. The substrates 23 moving along yet another path can include baked foods.
[0059] The substrate 23 moves along the delivery member 78 to a second location whereby the substrate 23 is aligned with at least one respective dosing station 36. The dosing machine 72 can include a plurality of dosing stations 36 whereby each of the dosing stations 36 is aligned with each of the delivery members 78. As described above, each of the delivery members 78 extends along a respective path 81. Thus, each of the dosing stations 36 is aligned with one of the respective paths 81 and configured to deliver the API to the substrate 23 moving along the respective path 81. In one embodiment, the substrate 23 can be positioned on the delivery member 78 such that one or more dosing heads 46 of the dosing stations 36 aligned with the respective paths are configured to deliver the API to only one substrate 23 at a time as the substrate 23 moves along the respective path 81. Specifically, the dosing heads 46 can be configured to deliver microdroplets to each individual substrate 23 in a manner described herein. Because the API is delivered in microdroplets, a precise, predetermined dose of the API is delivered to each of the substrates 23.
[0060] In one embodiment, the same API-containing liquid can be delivered to the multiple substrates 23. Alternatively, API-containing liquids having different API properties can be delivered to the different substrates 23. The different substrates 23 can define respective substrates. The substrates can move along different respective paths 81 to different dosing stations 36 operatively aligned with the respective paths 81. The dosing stations 36 can deliver respective APIs to the aligned substrates 23, either individually or as groups of substrates 23, each API having at least one API property different from the other APIs. Alternatively, the substrates 23 can move along the same path 81 to the same dosing station 36. Alternatively, the substrates 23 can move along different paths 81 to the same dosing station 36. The same dosing station can deliver a first API-containing liquid to the first at least one substrate 23, e.g., the first substrates 23. The same dosing station can deliver a second API-containing liquid to the second at least one substrate 23, e.g., the second substrates 23. The first and second APIs can have at least one API characteristic that differs from each other. The different API characteristics can include at least one of: 1) the concentration of the API; 2) the volume of the API delivered to the substrate during the delivery step, which can include at least one of different numbers of microdroplets and microdroplets having different volumes; 3) the composition of the API; 4) a modifier mixed with the API, configured to modify at least one of the flavor, mechanical properties, and aesthetics of the delivered API; and 5) the location of at least one dosing zone on the substrate 23 that defines the location on the substrate 23 where the API-containing liquid is to be deposited. The mechanical characteristics can include the viscosity of the API-containing liquid in some examples. The mechanical characteristics can further include the surface tension of the API-containing liquid delivered from the dosing station. It is further understood that the different API characteristics can include different predetermined doses delivered to the different substrates 23. In one example, the doses can be predetermined to correspond to a dosing regimen over a period of time.Thus, one or more groups of substrates can have doses that are different and designed to be consumed at predetermined times during the dosing regimen. For example, the doses can decrease over a period of time defined by the dosing regimen. Alternatively, each substrate 23 can receive an API-containing liquid 25 having the same API characteristic. Additionally, substrates in different groups can receive an API-containing liquid 25 having at least one different API characteristic, with all substrates within each group receiving the same API-containing liquid 25.
[0061] Alternatively, it is envisioned that a predetermined amount of substrate 23, or a plurality of substrates 23, such as dried fruits and / or nuts, may be grouped together on the delivery member 78 along respective paths 81. Thus, the dosing station 36 may be aligned with a group of substrates 23. Thus, the dosing head 46 may deliver a predetermined or targeted amount of API-containing microdroplets to the group as a whole, as opposed to each individual dried fruit or nut. Because the API is delivered in microdroplets, a precise, predetermined dose of API is delivered to the group of substrates 23. The group of substrates 23 may be intended to be consumed in a single serving. Thus, when the substrates 23 of the group are consumed, a precise, predetermined dose is consumed. It is recognized that the predetermined amount of substrates 23 to be dosed in a group is not limited to fruits and nuts, but to any type of edible product 24 designed to be consumed in large quantities, such as chips, popcorn, pretzels, candies such as gummy candies 45 (FIG. 4D), and the like. Thus, it should be understood that the addition station may be configured to deliver the API to at least one substrate 23 at a time, which may include a single substrate 23 or a group of substrates 23.
[0062] Each dosing station 36 may include at least one dosing head 46, such as an array of dosing heads 46, and one or more holding tanks 26 capable of housing a respective API-containing liquid 25 as described above. It is recognized that the multiple dosing stations 36 may receive the API-containing liquid 25 from a common one of the holding tanks. Alternatively, the dosing stations 36 may receive the API-containing liquid 25 from different holding tanks 26. The API-containing liquids 25 in the different holding tanks 26 may have different APIs from each other or may have the same API. Thus, the API may be a cannabinoid or any suitable alternative active pharmaceutical ingredient. Each of the at least one dosing heads 46 of the dosing stations 36 may be operatively aligned with each of the pathways 81 to deliver an active pharmaceutical ingredient to the at least one substrate 23 moving along each of the pathways 81. Thus, as the at least one substrate 23 moves along the respective pathway to a second location, the dosing station 36 delivers a predetermined amount of the API-containing liquid 25 from the at least one dosing head 46 to the respective aligned at least one substrate 23. The addition head 46 ceases delivery of the API-containing liquid 25 when the at least one substrate 23 has received a predetermined amount of liquid 25. The addition heads 46 of the array of addition heads 46 can be combined to deliver a predetermined amount of liquid 25 to respective different locations of the at least one substrate 23. That is, the locations of the at least one substrate 23 can be aligned with various addition heads 46 of the array of addition heads 46 that are aligned with respective pathways 81.
[0063] After each at least one substrate 23 has received a predetermined amount of liquid 25, the substrate 23 moves along the delivery member 78 past a second location. The dosing station 36 resumes delivery of liquid 25 when another at least one substrate 23 moves to the second location to a location aligned with the at least one dosing head 46. In this regard, each at least one substrate 23 arranged sequentially along the respective path 81 receives a predetermined amount of liquid 25 from the aligned one of the dosing stations 36. The predetermined amounts can be equal to each other or different from each other as desired, depending on the at least one substrate 23 and the desired dose of active pharmaceutical ingredient to be delivered to the at least one substrate 23. The dosing machine 72 can include a processor 102 (see FIG. 6) programmed with the dose to be applied to the substrate 23 moving along the at least one delivery member 78. The processor 102 can control the operation of the dosing station 36 and thus each of the dosing heads 46 described above. For example, the addition station 36 may include any suitable device or sensor to identify when one of the substrates 23 has moved into alignment with the addition head 46 and when a substrate 23 requiring delivery of liquid 25 is not aligned with the addition head 46 and communicate the alignment information to the processor 102. The processor 102 then controls the operation of the addition head 46.
[0064] Once the substrates 23 are loaded with the active pharmaceutical ingredient-containing liquid 25, the substrates 23 move along the delivery member 78 to a third location where they are delivered to the conveyor 38. In this regard, the delivery member 78 may be disposed in a spatial relationship with respect to the conveyor, and the substrates 23 may move from the delivery member 78 to the conveyor 38. In one embodiment, the delivery member 78 is supported by a delivery support member 82 of the adder 72. Thus, the support structure 76 may include a base 77 that supports the conveyor 38 and the packaging station 42, and a delivery support member 82 that supports the delivery member 78, in addition to the addition station 36, at least one holding tank 26, at least one hopper 76, and the post-processing station 40. The substrates 23 may be dried as they move from the second location to the third location. Thus, the adder 72 may include a post-processing station 40 between the second and third locations. The post-processing station may be configured as described above. Thus, the API can attach to the substrate 23 once the substrate 23 has been treated during the processing step.
[0065] The delivery support member 82 can support the delivery member 78 at a location above the conveyor 38, and the loaded substrate 23 can move downward from the support structure 78 towards the conveyor 38. In one embodiment, the loaded substrate 23 can move under gravity from the support structure 78 towards the conveyor 38. For example, the delivery member 78 can transport the substrate 23 to a third location defined by an opening 83 in the delivery support member 82. Thus, the substrate 23 can move through the opening 83 towards the conveyor 38. Alternatively, the third location can be configured as a conveyor or other suitable transport member configured to transport the substrate 23 towards the conveyor. The third location can be configured as a single opening or conveyor that receives loaded substrate 23 from all or multiple pathways 81. Alternatively, each pathway 81 can have its own dedicated third location.
[0066] The adder 72 may include a packaging station 42 that delivers a plurality of packages 86 to the conveyor 38. In one embodiment, the packages 86 are placed on the conveyor 38 upstream of the third location. The adder 72 may include a reservoir that contains a plurality of packages and may deliver the packages sequentially onto the conveyor 38. Alternatively, a separate machine may deliver the packages to the conveyor 38. The conveyor 38 moves the packages 86 to a position aligned with each of the third locations. Thus, at least one of the substrates 23 moving from the delivery member 78 toward the conveyor 38 is delivered into each package 86. In some embodiments, it is contemplated that a single added substrate, such as a baked food, is delivered into each package 86. In other embodiments, it is contemplated that multiple added substrates, such as dried fruits and / or nuts, are delivered into each package 82. For example, the multiple substrates 23 may be delivered from multiple paths 81 up to all paths 81 into a single respective container 82. Alternatively, one or more conveyors 38 can deliver packages to respective locations such that packages 82 receive their respective at least one substrate 23 from each of the multiple paths 81 via a dedicated third location. Thus, packages 86 can receive their respective at least one substrate 23 simultaneously.
[0067] The packaging station 42 may further include a sealing station 88 configured to enclose the packages 86 after they receive their respective at least one substrate 23. In particular, the conveyor 38 delivers the packages 86 to the sealing station 88 after they receive their respective at least one substrate 23. The sealing station seals the packages 86 and may attach the packages 86 to themselves, for example, if the packages 86 are plastic bags or alternatively configured plastic packages. Alternatively, the sealing station 88 may deliver and fasten a cap onto the packages 86, for example, if the packages are configured as jars or other appropriately configured packages. The sealed packages may then be delivered to customers.
[0068] 6, the addition system 20 may further include a control system 100 configured to image successfully delivered microdroplets along the flow path as they travel from the addition head to the underlying substrate. It should be understood that the term "image" as used herein does not require that an actual image of the microdroplets be generated, but rather reflects the use of an imaging device positioned to capture at least one characteristic of the microdroplets as they travel along the flow path from the addition head to the underlying substrate. In particular, the control system 100 may include at least one detector, which may be configured as at least one camera 104 configured to capture at least one image of the microdroplets. The control system 100 may include a processor 102 in communication with the at least one camera 104 and configured to receive images from the at least one camera 104. The processor 102 may send control signals to either or both of the addition stations 36, including the addition head 46, depending on the characteristics captured by the at least one camera 104. The control system 100 may include a single processor 102 that receives signals from each of the at least one camera 104, although it should be understood that the control system 100 may alternatively include multiple processors that receive signals from or may be integrated into each camera.
[0069] As described in more detail below, in one embodiment, the at least one camera 104 can detect an edge boundary of each microdroplet as it travels along the flow path from the application head to the substrate. Alternatively or additionally, the at least one camera 104 is configured to detect an optical property, such as fluorescence, of each microdroplet as it travels along the flow path from the application head to the substrate. Still alternatively or additionally, the at least one camera 104 is configured to capture Raman scattering of light passing through each microdroplet as it travels along the flow path from the application head to the substrate. The Raman scattering can be resonant Raman scattering or non-resonant Raman scattering. It should further be understood that any of the at least one camera 104 can detect the presence of each microdroplet along the flow path as it travels successively from the application head to the common substrate. Thus, the total amount of microdroplets delivered to each common substrate can be determined. Thus, the characteristics of the microdroplets that are imaged may include at least one or more, and up to all of the following: the size of the microdroplet, the light scattering properties of the microdroplet, the fluorescence of the microdroplet, one or more edge boundaries of the microdroplet, and the presence of the microdroplet within the flow channel. Each camera is now described in further detail.
[0070] 7-8C, the cameras of the control system 100 are described in one embodiment. With reference to FIG. 7, the at least one camera 104 can include a first detector or camera 111 configured to measure the size of the microdroplets. The first camera 111 can be focused on a first location 108 of each of the flow paths 110 to capture images of the microdroplets as they travel along the flow path from the application head 46 to the underlying substrate. The first camera 111 can then capture images of the microdroplets as they pass by the location. The first camera 111 can communicate with the processor 102 to identify each microdroplet as it travels along the flow path. In this regard, the processor 102 can count the number of microdroplets that are being delivered to each underlying substrate. The first camera 111, and all cameras described herein, can image the microdroplets along an imaging trajectory that intersects with each location of the respective flow path. In one embodiment, the imaging trajectory is substantially perpendicular to the flow path. In other embodiments, the trajectory may define an oblique angle relative to the flow path.
[0071] Additionally, the first camera 111 can detect edge boundaries of each microdroplet as it travels along the flow path. In some embodiments, the control system 100 can include a first light source 106 that directs a first light beam 112 to each first location 108 of the flow path 110. Thus, the first light beam 112 illuminates each microdroplet in the flow path as it passes through the first location 108. In one embodiment, the first light source 106 can be a light emitting diode (LED) that is directed through one or more filters to achieve uniform illumination in the first light beam 112. In one embodiment, the first light beam 112 can be a white light beam. The first light beam 112 can provide a uniform light intensity at each first location 108 through which the droplets fall. In one embodiment, the first locations 108 can be located in a plane oriented perpendicular to the flow path, and the first light beam 112 can travel along the plane through the first locations 108. Thus, the first camera 111 may be configured as a detector to detect the edges of each microdroplet.
[0072] The edges may be communicated to a processor that calculates the volume of each microdroplet. As discussed above, the microdroplets may become elongated as they move from the application head. However, surface tension of the microdroplets may cause the microdroplets to become more spherical as they move from the application head 46 to the substrate. Thus, in one embodiment, the cross-sectional dimension may be a maximum cross-sectional dimension that approximates the diameter of a sphere, and the volume of the microdroplets may be calculated as desired. In particular, the maximum distance between the outermost opposing edges of the microdroplets may be used to calculate the volume of a sphere having that maximum distance as its diameter. As successive microdroplets are delivered to a common underlying substrate, the processor 102 may determine or calculate a total cumulative volume of liquid delivered to the substrate by adding up the respective volumes of the microdroplets delivered to the substrate. Based on the known concentration of API in the liquid, and thus in each microdroplet, and the volume of liquid delivered to the underlying substrate, the processor 102 may determine or calculate a total amount of API delivered to the substrate. Alternatively, as described in more detail below, the at least one camera 104 in FIG. 6 can include a camera that provides image data of the API in each microdroplet, which enables the processor 102 to determine the volume of the API in each microdroplet based at least in part on the image data of the API.
[0073] In some examples, the processor 102 can compare the actual size of the microdroplets, determined as described above, to a predetermined size. The processor 102 can adjust an operating parameter to change the size of each of the microdroplets when the actual size is outside of an acceptable range from the predetermined size. In one example, the size can be a volume, as described above. In another example, the size can be a maximum distance between the opposing outermost edges. When the actual size is outside of an acceptable range and larger than the predetermined size, the processor 102 can decrease at least one or both of the stroke length and stroke speed of the pump, thereby reducing the actual size. When the actual size is outside of an acceptable range and smaller than the predetermined size, the processor 102 can increase at least one or both of the stroke length and stroke speed of the pump, thereby increasing the actual size. Alternatively or additionally, parameters other than the stroke length and stroke speed of the pump can be employed to change, e.g., reduce, the microdroplet size. Similarly, the processor 102 can compare the actual amount of cannabis in each of the microdroplets to a predetermined amount of API to be included in each of the microdroplets. The processor 102 can adjust operating parameters to change the amount of API being delivered in each microdroplet. For example, if the actual amount of API in the microdroplet is outside of the tolerance range and is greater than the predetermined amount of API in the microdroplet, the processor 102 can decrease at least one or both of the pump's stroke length and stroke rate, thereby decreasing the actual volume of the microdroplet, thereby decreasing the amount of API in the microdroplet. If the actual amount of API in the microdroplet is outside of the tolerance range and is less than the predetermined amount of API in the microdroplet, the processor 102 can increase at least one or both of the pump's stroke length and stroke rate, thereby increasing the actual size, thereby increasing the amount of API in the microdroplet.When the pump stroke length, stroke speed, or parameters other than the pump stroke length and stroke speed are varied from their respective initial parameter values to their respective final parameter values to change the microdroplet size, the processor 102 can execute a routine to impart a substantially “S” shaped transition from the initial parameter value to the final parameter value, thereby improving performance by minimizing temporary instabilities in the microdroplet size.
[0074] It is recognized that a number of parameters can affect the size of the microdroplets generated and delivered to the substrate. Some parameters can have a greater effect on the size of the microdroplets than others. In one embodiment, the processor 102 can maintain a selected set of parameters at settings determined to have a reduced effect on the size of the microdroplets delivered from the addition head, respectively, when those settings are adjusted, compared to the effect of adjusting the settings if not included in the set of parameters. As shown in FIG. 9, where the x-axis and z-axis can define the parameters within the selected set of parameters and the y-axis is the size of the microdroplets, the generated curve defines a stability zone 105 where adjustments of the x-axis and z-axis have a reduced effect on the y-axis as opposed to elsewhere on the curve.
[0075] 6-7, as will now be described, based on the images captured by the first camera 111 of the microdroplets delivered to the substrates, the control system 100 can determine the total actual volume of liquid delivered to each substrate. The processor 102 can compare the total actual volume of liquid delivered to the substrate with a predetermined volume of liquid to be delivered to the substrate. As will be understood from the following description, the control system 100, and in particular the processor 102, can stop the step of delivering the microdroplets to the substrate when the total actual volume is within about 10% of the predetermined volume of liquid. That is, the processor 102 can prevent liquid from moving out of the reservoir and out of the dosing head. In one embodiment, the total actual volume can be within about 5% of the predetermined volume of liquid. For example, the total actual volume can be within about 1% of the predetermined volume of liquid.
[0076] It is understood that the desired amount of API to be delivered to the substrate can be predetermined before the delivery of the microdroplets. Thus, the volume of liquid to be delivered to the substrate can also be predetermined before the delivery of the microdroplets based on the known concentration of API in the liquid and the desired dose of API to be applied to each substrate. The processor 102 can continue to deliver microdroplets to each substrate until the processor 102 determines that the total amount of API delivered to the substrate by the immediately following microdroplets exceeds a predetermined amount of API to be delivered to the substrate or the total volume of liquid delivered to the substrate by the immediately following microdroplets exceeds a predetermined volume. An immediately following microdroplet means that no additional microdroplets are delivered between the immediately preceding delivered microdroplet and that microdroplet.
[0077] In one example, processor 102 can deliver a single immediately succeeding microdroplet if delivery of the single immediately succeeding microdroplet would cause the total amount of API or total volume of liquid delivered to the underlying substrate to approach the predetermined amount of API or the predetermined volume of liquid, respectively, compared to ceasing delivery of the microdroplet to the substrate prior to delivery of the single immediately succeeding microdroplet. This process can continue until processor 102 determines that delivery of the immediately succeeding microdroplet to the substrate would cause the total amount of API or total volume of liquid to move away from the predetermined amount of API or the predetermined volume of liquid, respectively, compared to ceasing delivery of the microdroplet to the substrate prior to delivery of the single immediately succeeding microdroplet. At such a determination, processor 102 can cease delivery of the microdroplet to the substrate and instead cause a microdroplet to be delivered to the subsequent substrate.
[0078] In other examples, when the processor 102 determines that the total amount of API delivered to the substrate by the delivery of the immediately following microdroplet will exceed a predetermined amount of API, or the total volume of liquid delivered to the substrate by the delivery of the immediately following microdroplet will exceed a predetermined volume, the processor 102 can stop the delivery of the microdroplet to the substrate and can instead deliver a microdroplet to the subsequent substrate. Alternatively, the processor 102 can stop the delivery of the microdroplet immediately after the delivery of the immediately following microdroplet if the total volume of liquid or the total amount of API delivered to the substrate is greater than the predetermined volume of liquid or the predetermined amount of API, respectively. The term "immediately after" in this context means that no further microdroplets are delivered. In other examples, the processor 102 can stop the delivery of the microdroplet to the substrate if the current amount of API or the total volume of liquid delivered to the substrate is less than a desired amount of the desired amount of API or the predetermined total volume of liquid to be delivered to the substrate by a desired value.
[0079] In yet another example, the processor 102 can compare the current difference between the total amount of API or volume of liquid delivered to the substrate and the predetermined amount of API or volume of liquid. The processor 102 can determine an average amount of API per microdroplet and / or an average volume of liquid per microdroplet. The processor 102 can then add the average amount of API per microdroplet or the average volume of liquid per microdroplet to the total amount of API or volume of liquid delivered to the substrate to arrive at a sum. The processor 102 can then determine a future difference between the resulting sum of the amount of API or volume of liquid and the predetermined amount of API or volume of liquid. If 1) the resulting sum of the average amount of API per microdroplet or the average volume of liquid per microdroplet and the total amount of API or volume of liquid delivered to the substrate is greater than the predetermined amount of API per microdroplet or the predetermined volume of liquid, respectively, and 2) the future difference is less than the current difference, the processor 102 can allow delivery of the next microdroplet immediately before ceasing delivery of the microdroplets to the substrate. In one example, the processor 102 may allow delivery of only a single immediately subsequent microdroplet before ceasing delivery of the microdroplets to the substrate. It should be appreciated that in other examples, the processor 102 may cease delivery of microdroplets to the substrate when the current amount of API or total volume of liquid being delivered to the substrate is greater than a desired amount of API or a predetermined total volume of liquid to be delivered to the substrate by a desired value.
[0080] Thus, the processor 102 can determine in real time when delivery of a selected microdroplet to a substrate will 1) cause the total volume of liquid applied to the substrate to be greater than a predetermined volume of liquid, and / or 2) cause the total amount of API applied to the substrate to be greater than a predetermined amount of API. The selected microdroplet can be referred to as the immediately following microdroplet. Based on this determination, and because the microdroplets have substantially the same size, the processor 102 can halt delivery of the microdroplet to the substrate. In particular, the processor 102 can halt delivery of the microdroplet to the substrate if it is determined that delivery of the selected microdroplet will cause the total volume of liquid delivered to be greater than the sum of the predetermined volume of liquid and one-half the predicted volume of the selected microdroplet. Thus, it should be appreciated that the processor 102 can enable a selected microdroplet to be delivered if delivery of the selected microdroplet will cause the total volume of liquid delivered to be less than the sum of the predetermined volume of liquid and one-half the predicted volume of the selected microdroplet. The predicted volume of the selected microdroplet can be equal to the calculated average volume of liquid per microdroplet delivered to the substrate, or can be predicted based on any suitable surrogate data.
[0081] Alternatively or additionally, the processor 102 may cease delivery of the microdroplets to the substrate if it is determined that delivery of the selected microdroplets would result in a total amount of API delivered that is greater than the sum of a predetermined amount of API and one-half the predicted amount of API in the selected microdroplets. It should be understood that the processor 102 may thus allow a selected microdroplet to be delivered if delivery of the selected microdroplets would result in a total amount of API delivered that is less than the sum of a predetermined volume of liquid and one-half the predicted amount of API in the selected microdroplets. The predicted amount of API in the selected microdroplets may be equal to the calculated average amount of API per microdroplet delivered to the substrate, or may be predicted based on any suitable alternative data.
[0082] Since the total amount of API applied to the substrate can be within half the amount of API in the microdroplet for a given amount of API, and since 10-500 microdroplets, e.g., 100-500 microdroplets, can be delivered to a given substrate, the total amount of API applied to the substrate can be within a range that deviates from the given desired or optimal amount of API by an amount within a range of about 0.5% to about 0.1% of the given amount of API. Similarly, since the total volume of liquid applied to the substrate can be within half the volume of liquid in the microdroplet for a given volume of liquid, and since 100-500 microdroplets can be delivered to a given substrate, the total volume of liquid applied to the substrate can be within a range that deviates from the given volume of liquid by an amount within a range of about 0.1% to about 10%, e.g., about 0.1% to about 5%, e.g., about 0.1% to about 0.5% of the given volume of liquid. Of course, it will be recognized that as few as 2 microdroplets up to 500 or more microdroplets can be delivered to a given substrate, as desired.
[0083] Once the processor 102 has ceased delivery of microdroplets to a substrate, subsequent substrates may be doped with microdroplets according to any of the embodiments described above. Thus, it will be appreciated that by controlling the dose of API applied to each substrate as described above, the control system 100 can ensure that the dose of API delivered to each substrate is substantially equal to a predetermined or desired dose of the API. Additionally, the control system 100 can ensure that each substrate within a group of substrates committed to the same predetermined dose may all have a substantially equal dose level to one another.
[0084] When the dosing system 20 includes multiple dosing heads and multiple respective flow paths to a common substrate, the control system 100 may include a respective plurality of first cameras, each configured to image the microdroplets of a respective one of the flow paths. Thus, microdroplets delivered consecutively to the substrate along the respective flow paths may each be imaged by a single first camera as they travel along the same flow path. Microdroplets successfully delivered to the substrate along the respective flow paths from the respective dosing heads may be imaged by the respective first plurality of first cameras. In some embodiments, the imaged microdroplets described above may be referred to as a first plurality of microdroplets dispensed to the substrate along at least one first flow path from at least one first dosing head. As will be described, the control system 100 may cause at least one second microdroplet to be delivered to the substrate from the second dosing head. At least one second microdroplet may be delivered to the substrate along a corresponding second at least one flow path. The at least one second microdroplet may be configured as a plurality of second microdroplets delivered sequentially along a second flow path to a common substrate. Each of the first cameras 111 may image at least one second microdroplet along the second flow path in the manner described above. In some embodiments, a plurality of second microdroplets may be delivered along respective multiple flow paths to a common substrate, each of which is imaged by a respective first camera 111.
[0085] At least one second microdroplet can have a smaller amount of API than the amount of API in the first microdroplet. For example, at least one second microdroplet can be sized smaller than the microdroplets of the first plurality of microdroplets. Thus, the same API-containing liquid can be provided to each of the first and second dosing heads. In another example, at least one second microdroplet can be substantially equal to or larger in size than the first plurality of microdroplets, but can have a second concentration of API that is lower than the first concentration of API in the first plurality of microdroplets. Thus, a first reservoir of liquid containing a first concentration of API can provide the first liquid to the first dosing head, and a second reservoir containing a second concentration of API can provide the second liquid to the second dosing head.
[0086] Because the second amount of API in the at least one second microdroplet is less than the first amount of API in the first plurality of microdroplets, the at least one second microdroplet may be delivered when it is determined that the total amount of API or the total volume of liquid delivered to the substrate is approaching a predetermined amount of API or a predetermined volume of liquid, respectively. In one example, the processor 102 may determine when delivery of a selected second microdroplet of the at least one second microdroplet to the substrate causes the total amount of API delivered to the substrate to be greater than the predetermined amount of API, and in response, may cease delivery of the microdroplet to the substrate. The selected second microdroplet may be referred to as the immediately following second microdroplet.
[0087] In another example, the processor 102 can calculate a first API difference between the predetermined amount of API to be delivered to the substrate and the total amount of API that would be delivered to the substrate if the immediately following first microdroplet is delivered to the substrate. The processor 102 can calculate a second API difference between the predetermined amount of API to be delivered to the substrate and the total amount of API that would be delivered to the substrate if the immediately following first microdroplet is delivered to the substrate. If the first API difference is less than the second API difference, the processor 102 causes the immediately following first microdroplet to be delivered and prevents or stops the delivery of the at least one second microdroplet. If the second API difference is less than the first API difference, the processor 102 stops the delivery of the first microdroplet and delivers the at least one second microdroplet to the substrate. It should be understood that the API difference described above can be configured as an absolute value.
[0088] In one example, the processor 102 can continue to deliver at least one second microdroplet, which can include a plurality of second microdroplets, until the processor 102 determines that the total amount of API delivered to the substrate by the immediately following second microdroplet exceeds a predetermined amount of API to be delivered to the substrate. Alternatively, the processor 102 can continue to deliver at least one second microdroplet, which can be configured as a plurality of second microdroplets, until the processor 102 determines that the delivery of the immediately following second microdroplet to the substrate will cause the total amount of API delivered to the substrate to be further away from the predetermined amount of API compared to ceasing the delivery of the second microdroplet to the substrate prior to the delivery of the immediately following second microdroplet. At this point in time, the processor 102 can cease delivery of the microdroplet to the substrate. Once the processor 102 ceases delivery of the microdroplet to the substrate, the processor 102 can then cause a subsequent microdroplet to be delivered to the substrate in any manner described herein.
[0089] Since the microdroplets have substantially the same size, the processor 102 can halt the delivery of the microdroplets to the substrate if it is determined that the delivery of the selected second microdroplets will result in a total amount of API delivered to the substrate that is greater than the sum of the predetermined amount of API and one-half the predicted amount of API. It should be appreciated that the processor 102 can thus allow the selected second microdroplets to be delivered if the delivery of the selected second microdroplets will result in a total amount of API delivered to the substrate that is less than the sum of the predetermined amount of API and one-half the predicted amount of API. It should be further appreciated that the processor 102 can also halt the delivery of the microdroplets to the substrate immediately after delivering the immediately following second microdroplet if the amount of API delivered is greater than the predetermined amount of API. The predicted amount of API in the selected second microdroplets can be equal to the calculated average amount of API per second microdroplet delivered to the substrate, or can be predicted based on any suitable alternative data.
[0090] Similarly, processor 102 can determine when delivery of a selected one of the at least one second microdroplets to the substrate causes a total volume of liquid delivered to the substrate to be greater than a predetermined volume of liquid, and in response can abort delivery of the microdroplets to the substrate. In another example, processor 102 can calculate a first volumetric difference between the predetermined volume of liquid to be delivered to the substrate and a total amount of liquid that would be delivered to the substrate if the immediately following first microdroplet were delivered to the substrate. Processor 102 can calculate a second volumetric difference between the predetermined volume of liquid to be delivered to the substrate and a total volume of liquid that would be delivered to the substrate if the at least one second microdroplet is delivered to the substrate. If the first volumetric difference is less than the second volumetric difference, processor 102 causes delivery of the immediately following first microdroplet and prevents or aborts delivery of the at least one second microdroplet. If the second volume difference is less than the first volume difference, processor 102 ceases delivery of the first microdroplet and delivers at least one second microdroplet to the substrate. It should be understood that the volume difference described above may be configured as an absolute value.
[0091] In one example, processor 102 can continue delivery of at least one second microdroplet, which may include a plurality of second microdroplets, until processor 102 determines that the total volume of liquid delivered to the substrate by the immediately following second microdroplet exceeds a predetermined volume of liquid to be delivered to the substrate. Alternatively, processor 102 can continue delivery of at least one second microdroplet, which may be configured as a plurality of second microdroplets, until processor 102 determines that the delivery of the immediately following second microdroplet to the substrate will cause the total volume of liquid delivered to the substrate to be further away from the predetermined volume of liquid compared to ceasing delivery of the second microdroplet to the substrate prior to delivery of the immediately following second microdroplet. At this point in time, processor 102 can cease delivery of the microdroplet to the substrate and instead cause a microdroplet to be delivered to the subsequent substrate in any manner described herein.
[0092] Because the microdroplets have substantially the same size, the processor 102 can abort the delivery of a microdroplet to the substrate if it is determined that the delivery of the selected second microdroplet will cause the total volume of liquid delivered to the substrate to be greater than the sum of a predetermined volume of liquid and one-half the predicted volume of liquid. Thus, it should be appreciated that the processor 102 can allow the selected second microdroplet to be delivered if the delivery of the selected second microdroplet will cause the total volume of liquid delivered to the substrate to be less than the sum of a predetermined volume of liquid and one-half the predicted volume of liquid. It should further be appreciated that the processor 102 can also abort the delivery of a microdroplet to the substrate immediately after delivering the immediately following second microdroplet if the volume of delivered liquid is greater than the predetermined volume of liquid. The predicted volume of liquid of the selected second microdroplet can be equal to a calculated average volume of liquid per second microdroplet delivered to the substrate, or can be predicted based on any suitable alternative data.
[0093] From the above description, it should be understood that in some embodiments, the at least one second microdroplet is delivered only after the step of delivering the first plurality of microdroplets is completed. In other embodiments, the at least one second microdroplet, such as a plurality of second microdroplets, may be delivered during the delivery of the first plurality of microdroplets. That is, at least one of the first microdroplets may be delivered to the substrate both before and after the at least one second microdroplet is delivered to the substrate.
[0094] In yet another example, the dosing system may include an array of dosing heads, each of which is configured to deliver microdroplets of a respective size that differs from the size of one or more of the other dosing heads of the array. The processor 102 may control the delivery of microdroplets from selected ones of the array of dosing heads to dosing a substantially predetermined volume of liquid or a substantially predetermined dose of API to the underlying substrate. The microdroplets delivered from the dosing heads of the array may have substantially the same concentration of API, and substantially the same API. In one example, the processor may activate a first selected dosing head that delivers the largest microdroplet without exceeding a predetermined volume of liquid (or dose of API) to deliver one or more microdroplets. Upon determining that a subsequent microdroplet from the first selected dosing head will cause the total volume of liquid (or total dose of API) delivered to the substrate to exceed a respective predetermined value, the processor may stop operation of the first selected dosing head and activate a second selected dosing head that delivers the largest microdroplet without exceeding a predetermined volume of liquid (or dose of API) to deliver one or more microdroplets. It is understood that the microdroplets delivered by the second selected addition head are smaller in size than the microdroplets delivered by the first selected addition head. When it is determined that the total volume of liquid (or total dose of API) delivered to the substrate by the immediately following microdroplets from the first selected addition head exceeds the respective predetermined value, the processor can stop the operation of the second selected addition head and start the third selected addition head, which delivers the maximum microdroplets without exceeding the predetermined volume of liquid (or dose of API) to deliver one or more microdroplets. It is understood that the microdroplets delivered by the third selected addition head are smaller in size than the microdroplets delivered by the second selected addition head.The processor can continue to selectively activate subsequent dosing heads as the actual volume of liquid (and dose of API) approaches the respective predetermined values, with each dosing head delivering a microdroplet of a smaller volume than that delivered by the preceding dosing head. This process can continue until the predetermined volume or API is delivered, or until the dosing head delivering the smallest microdroplet is activated when the immediately following microdroplet either 1) causes the total volume of liquid or dose of API to exceed the respective predetermined value, or 2) causes a significant difference from the predetermined value compared to not delivering the immediately following microdroplet, at which point the dosing head delivering the smallest microdroplet can be deactivated. In one example, the microdroplet delivered from the dosing head delivering the smallest microdroplet can have a volume of about 1 nanoliter.
[0095] In yet another embodiment, it is recognized that one or more variable-sized dosing heads can be configured to deliver microdroplets having different sizes. Thus, the variable-sized dosing head can deliver one or more of its largest microdroplets until the delivery of the immediately following largest microdroplet would exceed the predetermined volume or API dose level. At such a time, the variable-sized dosing head can deliver one or more of the next largest microdroplets that do not cause the total volume or dose of the API to exceed the respective predetermined level, until it is determined that the immediately following largest microdroplet would exceed the predetermined volume or API dose level. The variable-sized dosing head can continue to selectively deliver smaller and smaller microdroplets until either the total volume of the liquid or the dose of the API 1) is equal to the respective predetermined value, or the immediately following microdroplet 2) exceeds the respective predetermined value, or 2) causes a significant difference from the predetermined value compared to not delivering the immediately following microdroplet, at which point the dosing head can be deactivated. In one embodiment, the smallest microdroplet delivered from the dosing head can have a volume of about 1 nanoliter.
[0096] With continued reference to FIG. 7, it should be understood that the first light source 106 and the first camera 111 may define any suitable configuration possible. In one embodiment, the first light source 106 and the first camera 111 may be supported by the adder 74 on either side of an axis including the flow path 110 in a location aligned with the flow path 110. Thus, the first light source 106 and the first camera 111 may be aligned directly with each other along a direction oriented perpendicular to the flow path. The first light beam 112 may travel from the first light source 106 through the microdroplets 62 to the first camera 111. If desired, one or more mirrors may direct the first light beam 112 from the first light source through the microdroplets 62 to the first camera 111. The first light beam 112 may travel along a direction perpendicular to the flow path 110 as it passes through the flow path 110. Alternatively, the first light beam 112 may travel along a direction oblique to the flow path 110 as it passes through the flow path.
[0097] 6 and 8A-8B, the at least one camera 104 can include a second detector or camera 118 configured to detect an optical property of each microdroplet as it travels along the flow path from the loading head to the substrate. Based on the optical property, the processor 102 can determine either or both of the volume of the API in the microdroplet and the constituents of the API in the microdroplet. In one example, the optical property can be the fluorescence of the API. In particular, the control system 100 can include a second light source 120 that directs a second light beam 122 to a second location 124 of each of the flow paths 110. The second location 124 of the flow paths 110 can be coincident with the first location or can be spaced apart from the first location. The second location 124 can be selected such that the microdroplet is substantially spherical at the second location 124, as described above.
[0098] A second light beam 122 can illuminate each microdroplet in the flow path as it passes through a second location 124. In one embodiment, the second light source 120 can be ultraviolet (UV) light at a wavelength that causes excitation of the API in the microdroplet as it passes through the second light beam 122, causing the API to fluoresce without causing the solvent, which can be an alcohol or the like as described herein, to fluoresce. The fluorescence of the API causes the API to emit light at an excitation wavelength that is different from the wavelength of the UV light of the second light source 120. The excitation wavelength is received by the second camera 118, which converts the light into a voltage that can be detected by any suitable device, such as an electrical circuit and, in some embodiments, a voltmeter. Based on a prior calibration correlating the voltage to the concentration of the fluorescing API in the microdroplet, the processor can determine the actual concentration of the API in each microdroplet passing through the second light beam 122 along the respective flow path.
[0099] As shown in FIG. 8A-FIG. 8B, the second light beam 122 may be reflected by at least one mirror 126 as it travels from the second light source 120 to the second camera 118. The second light source 120 and the second camera 118 may be structurally configured and positioned such that a plane passing through each of the second light source 120 and the second camera 118 also intersects with the flow path. In other words, the entire second light beam 122 may be present in a plane intersecting with the flow path. Furthermore, the second light source 120 and the second camera 118 may be in front of the flow path, and the mirror 126 may be disposed behind the flow path. The second light beam 122 may intersect with the flow path as it travels from the mirror 126 to the second camera 118. Alternatively, the second light beam 122 may intersect with the flow path as it travels from the second light source 120 to the mirror 126, as desired.
[0100] Now referring to FIG. 8C, the at least one camera 104 may include a third detector or camera 128 configured to detect the Raman and / or resonance Raman scattering spectrum of the API of each microdroplet as it travels along the flow path 110 from the dosing head 46 to the substrate. Based on the detected peak wavelengths of the Raman and / or resonance Raman scattering spectrum, the processor 102 may determine the molecular identity of each of the constituents of the API in the microdroplet, which may be any combination of a number of cannabis molecules. In particular, the control system 100 may include a third light source 130 that directs a third light beam 132 to a third location 134 of each of the flow paths 110. The third location 134 of the flow path 110 may coincide with either or both of the first and second locations, or may be spaced apart from each of the first and second locations. The third location 134 may be selected such that the microdroplet is substantially spherical at the second location 124, as described above.
[0101] The third light beam 132 can illuminate each microdroplet in the flow path as it passes through the second location 124. In one example, the third light source 130 can be a laser light at a wavelength that generates Raman and / or resonance Raman scattering as it passes through the API of each microdroplet. Based on the Raman and / or resonance Raman scattering, the processor 102 can determine the molecules of the API in each microdroplet, thereby ensuring that the API in each microdroplet has a predetermined desired composition. Furthermore, based on the Raman and / or resonance Raman scattering, the processor 102 can determine that the API is consistent between microdroplets being delivered to a common substrate. In another example, the third light source 130 or additional light source can be configured as an X-ray that generates X-ray scattering to identify the constituents of the API.
[0102] The third light beam 132 may be reflected off at least one mirror 126 (see FIG. 8B) as it travels from the second light source 120 to the second camera 118 in the manner described above with respect to the second light beam 122 shown in FIG. 8B. The third light source 130 and the third camera 128 may be spaced apart from the second light source 120 and the second camera 118 along an axis that defines the flow path. The third light beam 132 may be reflected off the same mirror as the second light beam 122 or a different mirror. Alternatively, the third light source 130 and the third camera 128 may be coplanar with the second light source 120 and the second camera 118, but the angle of incidence and the angle of reflection from the mirror 126 may be different from the angle of incidence and the angle of reflection of the second light beam 122. The third light beam 132 may intersect the flow path as it travels from the mirror 126 to the third camera 128. Alternatively, the third light beam 132 can intersect the flow path as it travels from the third light source 130 to the mirror, if desired. Further alternatively, the third light beam 132 can travel through the flow path from the third light source 130 to the third camera 128 without passing through a reflective surface.
[0103] It should be understood that any two or more up to all of the above-mentioned cameras, or additional cameras as desired, can be operated simultaneously to image the same microdroplets as they are dispensed from the addition head 46. It should further be understood that any one of the above-mentioned cameras, or additional cameras, can be operated simultaneously to detect the presence of each microdroplet moving along its respective flow path. The processor can count the number of microdroplets delivered to each substrate. In yet other embodiments, the control system 100 can perform reflectometry and / or interferometry of the microdroplets, both of which can reveal optical signatures of the API and / or solvent of the microdroplets. Thus, it should be understood that any one of the above-mentioned cameras, or additional cameras as desired, can non-invasively detect optical properties of the microdroplets or their API, as desired. For example, the optical property can be vibration. In another embodiment, the optical property can be fluorescence. In another embodiment, the optical property can be Raman and / or resonance Raman scattering. In another embodiment, the optical property can be X-ray scattering. In another example, the optical property can be the absorption of infrared photons that can reveal the optical signature of the API and / or solvent of the microdroplet. In this regard, the at least one light source can be configured as an infrared light source that can direct infrared light rays through the microdroplet according to any of the above-mentioned embodiments or any suitable alternative embodiment. Any of the above-mentioned optical diagnostic systems can be extended to a holographic format to generate a three-dimensional representation of one or more desired optical properties. The processor 102 can generate a hologram of the imaged microdroplet, which can include the dimensions and optical properties of the microdroplet obtained using any of the above-mentioned methods. In another example, the processor 102 can generate a tabular format of the dimensions and optical properties of the microdroplet obtained using any of the above-mentioned methods.
[0104] Method and system for adding cannabis to edible products From the above description, it should be appreciated that a method and apparatus are provided for converting an edible product or other substrate into a cannabis or other API-containing product with accurate repeatable and precise dosage. As described, the edible product or other substrate can be consistently dosed to avoid substantial variation in API dosage levels among a group of edible products or other substrates intended to have the same dosage of API. The method may include a step of delivering cannabis to a substrate, which may be an edible product or a non-edible product. The step of delivering may be performed with any suitable one or more applicators that deliver a predetermined dosage of cannabis. As used herein, the term "cannabis" refers to any extract from a marijuana or hemp plant, such as CBD, THC, or any alternative cannabinoid, alone or in combination with any one or more of the flavonoids or terpenes. The extract may be in its pure form or may be processed as desired, including, for example, an emulsified form of cannabis fluid. Although the present disclosure provides for the addition of at least one cannabis to a substrate, and thus cannabis is contemplated as a market for the final product, applications of the systems and methods disclosed herein that do not involve cannabis, including, but not limited to, other active pharmaceutical ingredients (APIs), are also possible and contemplated. For example, applications of the systems and methods disclosed herein can include, and are contemplated, active pharmaceutical ingredients (APIs) that include one or more cannabinoids, any alternative one or more over-the-counter (OTC) or prescription drugs, including those that provide either or both of a health benefit or a recreational drug experience, or other controlled ingestible substances. Thus, references herein to active pharmaceutical ingredients can include any one or more, up to and including all of the following: cannabis and cannabis plant-derived compounds, including one or more cannabinoids, either in natural oil form or in emulsified form, one or more over-the-counter drugs, one or more prescription drugs, one or more flavonoids, and one or more terpenes.References to active pharmaceutical ingredients herein may alternatively or / and additionally include one or more, up to all of the following: hallucinogenic or hallucinogenic ingredients, such as psilocybin and psilocin, and synthetic opioids, including synthetic opioid analgesics. It should be understood that the API may alternatively or additionally include fentanyl, recognizing that accurate doses of the type described herein may be important when administering APIs where an incorrect dose may have serious consequences. Similarly, references to one or more of the active pharmaceutical ingredients identified above may equally apply to any other of the active pharmaceutical ingredients identified above. According to one aspect of the present disclosure, the method of delivering cannabis or conventional drugs may also be used to deliver homeopathic remedies, herbal supplements with flavors or odors, and the like, to edible products. The resulting edible products may be referred to as "nutraceuticals," as the definition is "food containing health-imparting additives or having medicinal properties."
[0105] The active pharmaceutical ingredient can be added to a substrate to produce an active-containing substrate, which may include edible foods, edible non-food products, or other non-edible substrates. Edible foods can include, by way of example and not limitation, hard candy, chocolate brownies, cookies, soft candies such as gummy candies, savories such as trail mix bars or dried meat pieces, and the like. Thus, in some embodiments, the edible food can be a prepared food. In some specific embodiments, the edible food can be a baked food. The edible food can be bite-sized, such as M&M candies, gummy candies, chocolate kisses, and the like, or designed to require more than one bite to be consumed completely, such as cookies. Thus, in some embodiments, the edible food can include multiple mixed ingredients. As will be appreciated from the following description, the food can be fully prepared before adding the API to the food. In other embodiments, the API can be added during the preparation of the food. In some embodiments, the food can be a dehydrated food, such as dried fruit or jerky. In other embodiments, the edible product can be freeze-dried. In yet other examples, the edible product may be a raw food product such as nuts or fruit.
[0106] It will be appreciated that the application of active pharmaceutical ingredients to food products allows a wider range of foods to be produced with the active pharmaceutical ingredients. Furthermore, the API can be added more precisely compared to traditional methods. When the active pharmaceutical ingredients are applied to pre-prepared foods, APIs with short shelf lives are applied to a substrate and can be ingested in a short period of time compared to active pharmaceutical ingredients that are combined with raw ingredients that are later processed to prepare the food product. When the API is added during the food preparation process, the API can be added more precisely compared to traditional methods where the API is included in bulk ingredients that are mixed prior to cooking or baking.
[0107] In yet another embodiment, as described above, the substrate to which the API is added can be an edible non-food product. The primary purpose of a food product is to deliver nutrients, whereas the primary purpose of a non-food product is to deliver the API, either alone or with a carrier. Examples of edible non-food products can include dissolvable substances such as slips, or can be capsules, pills, tablets, nuggets, and the like. Alternatively, as described above, the substrate can be a non-edible product 33. That is, the substrate is not designed for human consumption, but is designed to be placed in the mouth. One such non-limiting example is a tongue depressor 35 (see FIG. 5E).
[0108] In one embodiment, multiple active-containing substrates can be provided as a set, with some of the substrates having different doses of active pharmaceutical ingredients and designed to be taken at different times during a period, such as different days of the week. Thus, a desired dose profile can be delivered to the patient over that period. Alternatively or additionally, one of the active-containing substrates can contain at least one different active pharmaceutical ingredient. Thus, a set of active-containing substrates can be designed to be taken sequentially (i.e., one after the other) over that period, thereby delivering a desired predetermined sequence of active pharmaceutical ingredients to the patient.
[0109] The API-containing liquid may be in the form of a pure API, such as a resin, or in the form of a concentration of the API in a liquid carrier, such as a solvent. The API-containing solid may be in the form of a pure API, such as a powder, or may be a mixture of the API and any other suitable material. The API-containing liquid and API-containing powder delivered to the substrate may be referred to as the API-containing material. In some examples, the applicator may deliver a trace amount of the active pharmaceutical ingredient to the substrate. For example, the trace amount may be delivered by the applicator as microdroplets, each having a volume ranging from about 2 nanoliters to about 10 microliters, such as about 25 nanoliters to about 2 microliters, carried by the solvent. For example, the microdroplets may have a volume ranging from about 25 nanoliters to about 1 microliter. The microdroplets may have a concentration of the API as desired. For example, the concentration of the API may range from about 50 micrograms per microliter of solution to about 1 milligram per microliter of solution. In other examples, the liquid may be a pure resin of the API.
[0110] In one embodiment, it is envisioned that applicators that deliver similar doses of API to similar substrates can deliver microdroplets of approximately the same size to the similar substrates. Thus, for example, when delivering API to dried fruits and / or nuts designed to have the same dose of API, the applicator can deliver approximately the same volume and number of microdroplets to each dried fruit and / or nut, or to a group of dried fruits and / or nuts, such as a serving.
[0111] As described in further detail below, a dosing head may be provided that is configured to deliver any suitable volume of microdroplets, such as the volumes described above. Thus, each microdroplet may contain a minute amount of API, ranging from about 0.1 micrograms to about 10 milligrams, for example, from about 1 milligram to about 2 milligrams. However, it is recognized that the microdroplets may have any volume as desired. It is further recognized that each microdroplet may contain a different amount of API, for example, depending on the volume of the microdroplet. The minute amount of API in the microdroplets allows for precise and accurate control of the dose of API delivered to the substrate. For example, each volume of microdroplets may be delivered to the substrate within a range of about 1% to about 10%, for example, about 5%, from the target volume of the microdroplets at 3 sigma. Thus, the dose of API in each microdroplet may be delivered to the substrate within a range of about 1% to about 10%, for example, about 5%, from the target dose at 3 sigma. The target volume of the microdroplets may vary based on the surface area or volume of the substrate to which the microdroplets are applied. Similarly, the dose of API to be delivered to the substrate can similarly be within the range of about 1% to about 10%, e.g., about 5%, at three sigma, from the target dose of API to the substrate, or a packaged portion of substrate, such as dried fruits or nuts. The target volume of the microdroplets can vary based on the surface area or volume of the substrate to which the microdroplets are applied.
[0112] Thus, in one embodiment, minute amounts can be delivered to a substrate in the form of microdroplets. The use of microdroplets can aid in precise and accurate dosing of active pharmaceutical ingredients compared to conventional techniques. The microdroplets can be delivered to the outer surface of the substrate by a 3D printer, an inkjet printer, or other suitable printing process. Alternatively or additionally, the microdroplets can be delivered to the outer surface of the substrate by precision spraying. Still alternatively or additionally, the microdroplets can be delivered to an internal location of the substrate surrounded by the outer surface. For example, the microdroplets can be delivered using an air gun that fires the microdroplets at the substrate with a burst of high pressure air (similar to how some vaccines and other drugs can be administered subcutaneously without the use of injection with a needle). Without being bound by theory, it is believed that microdroplets to an internal location of the substrate can also help facilitate administration or ingestion of potentially bitter tasting (or strong cannabis tasting) formulations by providing a means to add small amounts of such substances to a much larger amount of edible product.
[0113] Microdroplets containing the API may be delivered to the substrate. The microdroplets may include a solution containing at least one cannabis in liquid form as a solute mixed with any suitable solvent. To help achieve a predictable dosage of the at least one cannabis, the at least one cannabis may be substantially homogeneously mixed with the solute. Alternatively, the microdroplets may consist of or essentially be a refined, partially refined, or unrefined cannabis extract in liquid form with a desired viscosity that allows the cannabis extract to be reliably dispensed. In some examples, the liquid may be heated to achieve the desired viscosity without mixing the cannabis extract in the solute. In some examples, the microdroplets may be oily or hydrophilic in nature. For example, the microdroplets may be multi-layered with a protein or other protective coating surrounding a precise dose of an oil-based or water-based formulation. Since the concentration of cannabis in the liquid may be known, a volume of liquid may be predetermined and delivered to the substrate to achieve the desired predetermined approximate dosage of cannabis. In some other examples, the microdroplets may be of emulsified cannabis liquid.
[0114] In other embodiments, the active pharmaceutical ingredient, which may include one or more cannabinoids, terpenes, and / or flavonoids, may be added to the substrate in granular form. For example, cannabis extract, which may be refined, partially refined, or unrefined, may be delivered to the substrate as a powder. In some examples, cannabis may be crystallized and ground to produce a powder. Since the concentration of cannabis in the powder may be known, a mass of powder may be predetermined and delivered to the substrate to achieve a desired dosage of cannabis.
[0115] The liquid or powder to be delivered to the substrate can contain a single desired cannabis. Thus, a single desired cannabis can be delivered to the substrate. Alternatively, multiple different liquids or powders can be delivered to the substrate, each containing their own different one or more cannabis components. Thus, by delivering multiple different liquids and powders, multiple desired cannabis components can be delivered to the substrate. The liquids and powders can be delivered in equal or different amounts. Thus, the ratio of one or more cannabis components to one or more other cannabis components can be controlled. In other examples, the liquid or powder to be delivered to the substrate can contain multiple cannabis components in equal or desired proportions. Thus, a single liquid or powder can be delivered to the substrate to deliver either a single cannabinoid or multiple cannabis components. Multiple cannabis components delivered to the food product using one or more powders or liquids can include two or more cannabis components up to the full range of cannabis components, for example, about 113 cannabinoids.
[0116] In some embodiments, the formulation used for addition to the edible product may contain a substantial fraction of any suitable cannabinoid. Non-limiting examples of such cannabinoids include THC or CBD, or a combination of one or both of these with other cannabinoids. In some embodiments, the API may include a terpene or flavonoid, alone or in combination with one or more cannabinoids. The terpene and / or flavonoid may be extracted from cannabis or hemp, or may be provided as a pure substance commercially obtained or synthesized from other sources. Furthermore, bitter or strong cannabis flavors may be hidden in the much more dominant flavors of the "host" edible product. Alternatively or additionally, the at least one cannabinoid may be deposited in a location of the product that is not designed to be directly first contacted with the tongue during ingestion, thereby further masking the taste of the at least one cannabinoid. For example, the at least one cannabinoid may be applied to the top round surface of a cookie, recognizing that the cookie is designed to be placed in the mouth with the bottom flat surface against the tongue. Alternatively or additionally, the microdroplets may be coated with sugar or other suitable taste-masking agent, as desired.
[0117] In some embodiments, soft edible products such as chocolate, gummies, licorice, etc. can be used as a "carrier" or "host" for an amount of cannabinoids that can be injected into the soft edible product (by air gun, needle, or other suitable method known in the art) to force the added material into the bulk of the soft edible product. The flavor of cannabis can be masked by such an approach. In some embodiments, energy such as infrared light, forced air, or microwaves can be applied to the surface of the edible product to soften (or further soften) the material in small areas, allowing cannabis or hemp-derived material to be more easily injected (or to a greater depth into the host edible product) into the infrared pre-treated areas. Energy can be applied before injection, after injection, or both before and after injection. In other examples, at least one cannabis can be applied to multiple surfaces of the edible product up to the entire surface of the edible product.
[0118] In some embodiments, the at least one cannabis may be mixed with a food ingredient immediately prior to packaging or delivery of the prepared edible product (e.g., as a component of an icing or other coating, or as part of a sugar coating applied to a gummy candy), particularly if such an ingredient is suitable for addition. In some embodiments, the edible product may be coated with a coating of small oil globules or solid powders, each containing at least one cannabis, to block the taste or mask the cannabinoid flavor. In some embodiments, a coloring agent may be added to the at least one cannabis prior to delivery to the edible product, in order to blend the compound blend with the color of the edible product.
[0119] According to one embodiment, the applicator can deliver successive microdroplets containing the API to the underlying substrate under gravity. In another embodiment, the applicator can deliver successive microdroplets containing the API to the underlying substrate under positive pressure, where the positive pressure and gravity contribute to the velocity of the microdroplets as they travel from the applicator to the substrate. In some embodiments, the microdroplets travel along a vertical path to the underlying substrate. In other examples, the path can include a horizontal component.
[0120] According to one embodiment, energy is applied to the surface of the edible product to increase the adhesion of the API-containing material to the edible product. According to one embodiment, energy is applied to increase the temperature of the surface. In one embodiment, the temperature can be increased by directing at least one of forced air, microwaves, and light such as infrared light at the surface. Energy can be applied before delivering the API-containing material to the edible product, after delivering the API-containing material to the edible product, or both before and after delivering the API-containing material to the edible product.
[0121] It should be noted that the illustration and discussion of the embodiments and examples shown in the figures are for illustrative purposes only and should not be construed as limiting the disclosure. Those skilled in the art will appreciate that the present disclosure contemplates various possible modifications of the various aspects, embodiments and examples described herein. Furthermore, it should be understood that the concepts described above with the above-mentioned embodiments and examples may be used alone or in combination with any of the other embodiments and examples described above. Furthermore, it should be understood that the various alternatives described above with respect to one illustrated embodiment may be applied to all other embodiments and examples described herein, unless otherwise indicated. Accordingly, reference is made to the claims.
[0122] [Embodiment] (1) A method for limiting error rates in an API dosing system, comprising: continuously delivering microdroplets of a liquid from at least one dosing head along a path to a substrate, said liquid containing a quantity of an active pharmaceutical ingredient; imaging the successively delivered microdroplets at locations along the path between the at least one dispense head and the substrate; determining a total volume of the liquid delivered to the substrate based on the imaging step; and A method comprising: (2) comparing the total volume of the liquid delivered to the substrate with a predetermined volume of liquid to be delivered to the substrate; Ceasing the delivering step when the total volume is within a selected tolerance, such as within 10% or 1% of a predetermined volume of liquid; 2. The method of embodiment 1, further comprising: (3) The method of embodiment 1, further comprising determining in real time when delivery of selected microdroplets to the substrate causes a total volume of the liquid to be greater than a predetermined volume of the liquid. (4) The method of embodiment 3, further comprising the step of ceasing the delivery based on the determining step. (5) The method of claim 4, comprising performing the aborting step before delivering the selected microdroplets if the delivery of the selected microdroplets would cause a total volume of the liquid delivered to be greater than a predetermined volume of the liquid plus one-half the predicted volume of the selected microdroplets.
[0123] (6) The method of claim 5, comprising enabling the selected microdroplets to be delivered if the delivery of the selected microdroplets would result in a total volume of the delivered liquid being less than the sum of the predetermined volume of the liquid and one-half the predicted volume of the selected microdroplets. (7) The method of claim 5, comprising performing the aborting step immediately after delivering the selected microdroplets if the total volume of the liquid delivered is greater than a predetermined volume of the liquid. (8) A method according to any one of claims 1 to 7, wherein all of the microdroplets are delivered sequentially from a single dosing head, and the imaging step includes imaging each of the microdroplets with a single camera. (9) The method of claim 2, wherein the delivering step includes delivering a first plurality of the microdroplets to the substrate from a first application head and delivering at least one second microdroplet to the substrate from a second application head. 10. The method of claim 9, wherein the at least one second microdroplet is smaller in size than the first plurality of microdroplets.
[0124] (11) The method of any of embodiments 9 to 10, further comprising determining in real time when delivery of a selected one of the at least one second microdroplet to the substrate causes a total volume of the liquid to be greater than a predetermined volume of the liquid. (12) The method of embodiment 11, further comprising a step of ceasing the delivering step based on the determining step. (13) The method of embodiment 12, comprising performing the aborting step before delivering the selected second microdroplets if the delivery of the selected second microdroplets would cause a total volume of the liquid delivered to be greater than a predetermined volume of the liquid plus one-half the predicted volume of the selected second microdroplets. (14) The method of any of embodiments 12 to 13, comprising enabling the selected second microdroplets to be delivered if the delivery of the selected second microdroplets would result in a total volume of the delivered liquid being less than the sum of a predetermined volume of the liquid and one-half the predicted volume of the selected second microdroplets. (15) The method of embodiment 14, comprising performing the ceasing step immediately after delivering the selected second microdroplet if the total volume of the liquid delivered is greater than a predetermined volume of the liquid.
[0125] (16) The method of any one of claims 9 to 15, wherein the imaging step includes imaging the first plurality of microdroplets with a first camera and imaging the at least one second microdroplet with a second camera. (17) The method of any one of embodiments 9 to 16, wherein the at least one second microdroplet is delivered while the step of delivering the first plurality of microdroplets is being performed. (18) The method of any one of embodiments 9 to 16, wherein the at least one second microdroplet is delivered only after the step of delivering the first plurality of microdroplets is completed. (19) The method of any one of embodiments 9 to 18, wherein the at least one second microdroplet comprises a plurality of second microdroplets. (20) The method of any one of the preceding claims, wherein the delivering step comprises delivering between 10 and 500 microdroplets to the substrate.
[0126] 21. The method of claim 1, wherein the delivering step comprises delivering between 2 and 500 microdroplets. (22) The method of any one of the preceding claims, wherein the substrate is a bite-sized edible food product. (23) The method of any one of claims 1 to 22, wherein the imaging step is performed at a location along the path where the microdroplet becomes substantially spherical. (24) The method of any one of the preceding claims, wherein each of the microdroplets has a volume ranging from about 2 nanoliters to about 10 microliters. (25) The method of any one of the preceding claims, further comprising the steps of comparing an actual size or an actual size and shape of at least one of the microdroplets to a predetermined size or shape, and adjusting a parameter for modifying the size of each of the microdroplets if the actual size is outside an acceptable range from the predetermined size or shape.
[0127] (26) The method of claim 23, further comprising the step of decreasing at least one of a stroke length, a stroke rate, or other system parameter if the actual size is greater than the predetermined size outside the tolerance range. (27) The method of claim 23, further comprising increasing at least one of a stroke length, a stroke rate, or other system parameter if the actual size is outside the tolerance range and less than the predetermined size. (28) The method of any of the preceding claims, comprising generating and delivering the microdroplets under settings of a selected set of parameters that are determined to have a reduced effect on the size of the microdroplets when adjusted compared to the effect of adjusting the settings if the settings are not included in the set of parameters. (29) The method of any one of the preceding claims, wherein determining the total volume of the liquid delivered to the substrate comprises measuring a size of each of the microdroplets during the imaging step. 30. The method of claim 24, wherein determining the total volume of the liquid delivered to the substrate further comprises calculating a volume of each of the delivered microdroplets from the measured respective sizes and adding up the respective volumes of the delivered microdroplets.
[0128] (31) The method of any one of claims 1 to 28, wherein the imaging step includes optical imaging, including any one or more of performing UV imaging of the microdroplets, reflectometry of the microdroplets, interferometry of the microdroplets, Raman and / or resonance Raman scattering of the microdroplets, UV fluorescence of the microdroplets, infrared imaging of the microdroplets, and X-ray scattering of the microdroplets. (32) A method according to any one of the preceding claims, wherein the imaging step is performed along a trajectory that intersects with the path. (33) The method of embodiment 32, wherein the trajectory is substantially perpendicular to the path. (34) The method of claim 32, wherein the trajectory is at an oblique angle to the path. (35) The method of any one of the preceding claims, wherein the API comprises cannabis.
[0129] (36) The method of embodiment 35, wherein the cannabis contains cannabinoids including at least one of TCH and CBD. (37) The method of any one of the preceding claims, wherein the API comprises cannabis and the liquid contains the cannabis in a concentration ranging from about 50 micrograms per microliter of solution to about 1 milligram per microliter of solution. (38) The method of any one of the preceding claims, wherein each of the microdroplets contains a respective microgram of cannabis in the range of about 0.1 micrograms to about 10 milligrams. (39) The method of any one of the preceding embodiments, wherein the API comprises at least one flavonoid. (40) The method of any one of the preceding claims, wherein the API comprises at least one terpene.
[0130] (41) The method of any one of the preceding claims, wherein the API comprises at least one of psilocybin and psilocin. (42) The method of any one of the preceding claims, wherein the API comprises a synthetic opioid. (43) The method of any one of the preceding claims, further comprising varying the size of the microdroplets by varying a parameter from an initial parameter value to a final parameter value along a substantially “S” shaped transition. (44) A method for limiting error rates in an API dosing system, comprising: continuously delivering microdroplets of a liquid from at least one dosing head along a path to a substrate, the liquid containing a quantity of an API; imaging the successively delivered microdroplets at locations along the path between the at least one dispense head and the substrate; determining a total amount of the API delivered to the substrate based on the imaging step; and A method comprising: (45) The method of embodiment 44, further comprising the step of ceasing the delivering step when the total amount of API is within 10%, e.g., within about 1%, of a predetermined amount of API.
[0131] 46. The method of claim 45, wherein the determining step comprises determining a total volume of liquid delivered in the microdroplets during the delivering step, and determining the total amount of the API delivered based on a known concentration of the API in the liquid. (47) The method of embodiment 45, wherein the determining step comprises determining an individual volume of each of the API delivered in the microdroplets based on a size of each imaged microdroplet, and calculating the total volume of the API delivered as the sum of each of the individual volumes of the API delivered in each microdroplet. (48) The method of any of embodiments 45 to 47, further comprising determining in real time when delivery of selected microdroplets to the substrate results in the total amount of API being greater than the predetermined target amount of API. (49) The method of embodiment 45, comprising ceasing the delivery based on determining in real time when delivery of selected microdroplets to the substrate causes the total amount of API to be greater than the predetermined target amount of API. (50) The method of embodiment 49, comprising performing the aborting step before delivering the selected microdroplets if the delivery of the selected microdroplets would result in the total amount of the API being greater than the sum of the predetermined target amount of API and one-half the predicted amount of API in the selected microdroplets.
[0132] 51. The method of claim 50, comprising enabling the selected microdroplet to be delivered if the delivery of the selected microdroplet will result in the amount of the API being less than the sum of the predetermined volume of the liquid and one-half the predicted volume of the selected microdroplet. 52. The method of claim 51, comprising performing the discontinuing step immediately after delivering the selected microdroplets if the total amount of API is greater than the predetermined target amount of API. (53) The method of any one of embodiments 45 to 52, wherein all of the microdroplets are delivered sequentially from a single dosing head, and the imaging step includes imaging each of the microdroplets with a single camera. (54) The method of embodiment 45, wherein the delivering step includes delivering a first plurality of the microdroplets to the substrate from a first application head and delivering at least one second microdroplet to the substrate from a second application head. 55. The method of claim 54, wherein the at least one second microdroplet is smaller in size than the first plurality of microdroplets.
[0133] (56) The method of any of embodiments 54 to 55, further comprising determining in real time when delivery of selected ones of the at least one second microdroplet to the substrate results in the total amount of API being greater than the predetermined target amount of API. (57) The method of any of embodiments 55 to 56, comprising ceasing the delivering step based on determining, in real time, when delivery of selected ones of the at least one second microdroplet to the substrate causes the total amount of API to be greater than the predetermined target amount of API. (58) The method of embodiment 57, comprising performing the aborting step before delivering the selected microdroplets if the delivery of the selected microdroplets would result in the total amount of the API being greater than the sum of the predetermined target amount of API and one-half the predicted amount of API in the selected microdroplets. (59) The method of embodiment 58, comprising enabling the selected microdroplet to be delivered if the delivery of the selected microdroplet would result in the total amount of the API being less than the sum of the predetermined target amount of API and one-half the predicted amount of API in the selected microdroplet. (60) The method of embodiment 59, comprising performing the discontinuing step immediately after delivering the selected microdroplets if the total amount of API is greater than the predetermined target amount of API.
[0134] (61) The method of any one of embodiments 54 to 60, wherein the imaging step includes imaging the first plurality of microdroplets with a first camera and imaging the at least one second microdroplet with a second camera. (62) The method of any one of embodiments 54 to 61, wherein the at least one second microdroplet is delivered while the step of delivering the first plurality of microdroplets is being performed. (63) The method of any of embodiments 54 to 61, wherein the at least one second microdroplet is delivered only after the step of delivering the first plurality of microdroplets is completed. (64) The method of any one of embodiments 54 to 61, wherein the at least one second microdroplet comprises a plurality of second microdroplets. (65) The method of any one of embodiments 44 to 64, wherein the delivering step comprises delivering between 10 and 500 microdroplets to the substrate.
[0135] (66) The method of embodiment 44, wherein the delivering step comprises delivering between 2 and 500 microdroplets to the substrate. (67) The method of any one of embodiments 44 to 66, wherein the substrate is a bite-sized edible food. (68) The method of any one of claims 44 to 67, wherein the imaging step is performed at a location along the path where the microdroplet becomes substantially spherical. (69) The method of any one of embodiments 44 to 68, wherein the liquid contains the API in a concentration ranging from about 50 micrograms per microliter of solution to about 1 milligram per microliter of solution. (70) The method of any one of embodiments 44 to 69, wherein each of the microdroplets contains a minute amount of each of the APIs in the range of about 0.1 micrograms to about 10 milligrams.
[0136] (71) The method of any one of embodiments 44 to 69, wherein each of the microdroplets has a volume ranging from about 2 nanoliters to about 10 microliters. (72) The method of any one of embodiments 45 to 69, further comprising the steps of comparing an actual amount of at least one API in the microdroplets with a predetermined target amount, and adjusting a parameter that changes the amount of each of the APIs in the microdroplets if the amount of API is outside an acceptable range from the predetermined amount of API. (73) The method of embodiment 72, comprising decreasing at least one of a stroke length, a stroke rate, or other system parameters if the actual amount of API exceeds the tolerance range from the predetermined amount of API. (74) The method of any one of embodiments 72 to 73, comprising increasing at least one of a stroke length, a stroke rate, or other system parameters if the actual amount of API falls below the tolerance range from the predetermined amount of API. (75) The method of any of embodiments 44 to 74, comprising generating and delivering microdroplets under a selected set of parameters determined to have a reduced impact on the size of the amount of API in each of the microdroplets when adjusted, compared to the impact of adjusting the settings when not included in the set of parameters.
[0137] (76) The method of any one of embodiments 44 to 75, wherein determining the total amount of the API comprises measuring a size of each of the microdroplets during the imaging step. 77. The method of claim 76, wherein the step of determining the total amount further comprises calculating an amount of each of the APIs in the microdroplets based on the measured respective sizes and adding together the calculated respective amounts of API. (78) The method of any one of embodiments 44 to 77, wherein the imaging step includes optical imaging or detection, including any one or more of: performing UV imaging or detection of the microdroplets, reflectance measurements of the microdroplets, interferometry of the microdroplets, Raman and / or resonance Raman scattering of the microdroplets, UV fluorescence of the microdroplets, infrared imaging of the microdroplets, and X-ray scattering of the microdroplets. (79) A method according to any one of embodiments 44 to 78, wherein the imaging step is performed along a trajectory that intersects with the path. (80) The method of embodiment 79, wherein the trajectory is substantially perpendicular to the path.
[0138] (81) The method of embodiment 80, wherein the trajectory is at an oblique angle to the path. (82) The method of any one of embodiments 42 to 81, further comprising varying the size of the microdroplets by varying a parameter from an initial parameter value to a final parameter value along a substantially “S” shaped transition. (83) The method of any one of embodiments 42 to 82, wherein the API comprises cannabis. (84) The method of embodiment 83, wherein the cannabis contains cannabinoids including either or both of CBD and TCH. (85) The method of any one of embodiments 42 to 84, wherein the API comprises at least one flavonoid.
[0139] (86) The method of any one of embodiments 42 to 85, wherein the API comprises at least one terpene. (87) The method of any one of embodiments 42 to 82, wherein the API comprises at least one of psilocybin and psilocin. (88) The method of any one of embodiments 42 to 82, wherein the API comprises a synthetic opioid.
Claims
1. 1. A method for limiting error rates in an API addition system, comprising: continuously delivering microdroplets of a liquid from at least one dosing head along a path to a substrate, said liquid containing a quantity of an active pharmaceutical ingredient; imaging the successively delivered microdroplets at locations along the path between the at least one dispense head and the substrate; determining a total volume of the liquid delivered to the substrate based on the imaging step; and A method comprising:
2. comparing the total volume of liquid delivered to the substrate with a predetermined volume of liquid to be delivered to the substrate; Ceasing the delivering step when the total volume is within a selected tolerance, such as within 10% or 1% of a predetermined volume of liquid; The method of claim 1 further comprising:
3. 10. The method of claim 1, further comprising determining in real time when delivery of selected microdroplets to the substrate causes a total volume of the liquid to be greater than a predetermined volume of the liquid.
4. The method of claim 3 , further comprising ceasing the delivery based on the determining step.
5. 5. The method of claim 4, comprising performing the aborting step before delivering the selected micro-droplets if the delivery of the selected micro-droplets would cause a total volume of the liquid delivered to be greater than a predetermined volume of the liquid plus one-half a predicted volume of the selected micro-droplets.
6. 6. The method of claim 5, comprising enabling the selected micro-droplets to be delivered if the delivery of the selected micro-droplets will result in a total volume of the delivered liquid being less than the sum of a predetermined volume of the liquid and one-half a predicted volume of the selected micro-droplets.
7. 6. The method of claim 5, comprising performing the aborting step immediately after delivering the selected microdroplets if the total volume of the liquid delivered is greater than a predetermined volume of the liquid.
8. 8. The method of claim 1, wherein all microdroplets are delivered sequentially from a single dispense head, and the imaging step includes imaging each of the microdroplets with a single camera.
9. 3. The method of claim 2, wherein the delivering step comprises delivering a first plurality of the micro-droplets to the substrate from a first application head and delivering at least one second micro-droplet to the substrate from a second application head.
10. The method of claim 9 , wherein the at least one second microdroplet is smaller in size than the first plurality of microdroplets.
11. 11. The method of any one of claims 9-10, further comprising determining in real time when delivery of a selected one of the at least one second microdroplet to the substrate causes a total volume of the liquid to be greater than a predetermined volume of the liquid.
12. The method of claim 11 , further comprising the step of ceasing the delivering step based on the determining step.
13. 13. The method of claim 12, comprising performing the aborting step before delivering the selected second microdroplet if the delivery of the selected second microdroplet would cause a total volume of the delivered liquid to be greater than a predetermined volume of the liquid plus one-half a predicted volume of the selected second microdroplet.
14. 14. The method of any one of claims 12 to 13, comprising allowing the selected second microdroplet to be delivered if the delivery of the selected second microdroplet will result in a total volume of the delivered liquid being less than the sum of a predetermined volume of the liquid and one half a predicted volume of the selected second microdroplet.
15. 15. The method of claim 14, comprising performing the ceasing step immediately after delivering the selected second microdroplet if the total volume of the delivered liquid is greater than a predetermined volume of the liquid.
16. 16. The method of claim 9, wherein the imaging step comprises imaging the first plurality of microdroplets with a first camera and imaging the at least one second microdroplet with a second camera.
17. 17. The method of claim 9, wherein the at least one second microdroplet is delivered while the step of delivering the first plurality of microdroplets is being performed.
18. 17. The method of any one of claims 9 to 16, wherein the at least one second microdroplet is delivered only after the step of delivering the first plurality of microdroplets is completed.
19. 19. The method of claim 9, wherein the at least one second microdroplet comprises a plurality of second microdroplets.
20. 20. The method of any one of claims 1 to 19, wherein the delivering step comprises delivering between 10 and 500 microdroplets to the substrate.
21. The method of claim 1 , wherein the delivering step comprises delivering between 2 and 500 microdroplets.
22. 22. The method of any one of claims 1 to 21, wherein the substrate is a bite-sized edible food product.
23. 23. The method of claim 1, wherein the imaging step is performed at a location along the path where the microdroplet becomes substantially spherical.
24. 24. The method of any one of claims 1 to 23, wherein the microdroplets each have a volume in the range of about 2 nanoliters to about 10 microliters.
25. 25. The method of any one of claims 1 to 24, further comprising the steps of comparing an actual size or an actual size and shape of at least one of the microdroplets to a predetermined size or shape, and adjusting a parameter that alters the size of each of the microdroplets if the actual size is outside an acceptable range from the predetermined size or shape.
26. 24. The method of claim 23, comprising decreasing at least one of a stroke length, a stroke rate, or other system parameter if the actual size is greater than the predetermined size outside of the tolerance range.
27. 24. The method of claim 23, comprising increasing at least one of a stroke length, a stroke rate, or other system parameter if the actual size is outside of the tolerance range and less than the predetermined size.
28. 28. The method of any one of claims 1 to 27, comprising generating and delivering the microdroplets under settings of a selected set of parameters that are determined to have a reduced effect on the size of the microdroplets when adjusted compared to the effect of adjusting the settings if not included in the set of parameters.
29. 29. The method of any one of claims 1 to 28, wherein determining the total volume of the liquid delivered to the substrate comprises measuring a size of each of the microdroplets during the imaging step.
30. 25. The method of claim 24, wherein determining the total volume of the liquid delivered to the substrate further comprises: calculating a volume of each of the delivered microdroplets from the measured respective sizes; and adding the respective volumes of the delivered microdroplets.
31. 29. The method of any one of claims 1 to 28, wherein the imaging step comprises optical imaging, including any one or more of performing UV imaging of the microdroplets, reflectometry of the microdroplets, interferometry of the microdroplets, Raman and / or resonance Raman scattering of the microdroplets, UV fluorescence of the microdroplets, infrared imaging of the microdroplets, and X-ray scattering of the microdroplets.
32. 32. The method of claim 1, wherein the imaging step is performed along a trajectory that intersects with the path.
33. 33. The method of claim 32, wherein the trajectory is substantially perpendicular to the path.
34. 33. The method of claim 32, wherein the trajectory is at an oblique angle to the path.
35. 35. The method of any one of claims 1 to 34, wherein the API comprises cannabis.
36. 36. The method of claim 35, wherein the cannabis comprises cannabinoids including at least one of TCH and CBD.
37. 37. The method of any one of claims 1 to 36, wherein the API comprises cannabis and the liquid contains the cannabis in a concentration ranging from about 50 micrograms per microliter of solution to about 1 milligram per microliter of solution.
38. 38. The method of any one of claims 1 to 37, wherein each of the microdroplets contains a respective microgram of cannabis in the range of about 0.1 micrograms to about 10 milligrams.
39. 39. The method of any one of claims 1 to 38, wherein the API comprises at least one flavonoid.
40. 40. The method of any one of claims 1 to 39, wherein the API comprises at least one terpene.
41. 35. The method of any one of claims 1-34, wherein the API comprises at least one of psilocybin and psilocin.
42. 35. The method of any one of claims 1 to 34, wherein the API comprises a synthetic opioid.
43. 43. The method of any one of claims 1 to 42, further comprising varying a size of the microdroplets by varying a parameter from an initial parameter value to a final parameter value along a substantially "S" shaped transition.
44. 1. A method for limiting error rates in an API addition system, comprising: continuously delivering microdroplets of a liquid from at least one dosing head along a path to a substrate, said liquid containing a quantity of an API; imaging the successively delivered microdroplets at locations along the path between the at least one dispense head and the substrate; determining a total amount of the API delivered to the substrate based on the imaging step; and A method comprising:
45. 45. The method of claim 44, further comprising the step of ceasing the delivering step when the total amount of the API is within 10%, such as within about 1%, of a predetermined amount of API.
46. 46. The method of claim 45, wherein the determining step comprises determining a total volume of liquid delivered in the microdroplets during the delivering step, and determining the total amount of the API delivered based on a known concentration of the API in the liquid.
47. 46. The method of claim 45, wherein the determining step comprises determining an individual volume of each of the API delivered in the microdroplets based on a size of each imaged microdroplet, and calculating the total volume of the API delivered as the sum of each of the individual volumes of API delivered in each microdroplet.
48. 48. The method of any one of claims 45 to 47, further comprising determining in real time when delivery of selected microdroplets to the substrate results in the total amount of API being greater than the predetermined target amount of API.
49. 46. The method of claim 45, comprising ceasing the delivery based on determining, in real time, when delivery of selected microdroplets to the substrate causes the total amount of the API to be greater than the predetermined target amount of API.
50. 50. The method of claim 49, comprising performing the aborting step prior to delivering the selected microdroplets if the delivery of the selected microdroplets would result in the total amount of the API being greater than the sum of the predetermined target amount of API and one-half of a predicted amount of API in the selected microdroplets.
51. 51. The method of claim 50, comprising enabling the selected microdroplet to be delivered if the delivery of the selected microdroplet will result in the amount of the API being less than the sum of the predetermined volume of the liquid and one-half the predicted volume of the selected microdroplet.
52. 52. The method of claim 51, comprising performing the discontinuing step immediately after delivering the selected microdroplets if the total amount of API is greater than the predetermined target amount of API.
53. 53. The method of any one of claims 45 to 52, wherein all of the microdroplets are delivered sequentially from a single dispense head, and the imaging step includes imaging each of the microdroplets with a single camera.
54. 46. The method of claim 45, wherein the delivering step comprises delivering a first plurality of the micro-droplets to the substrate from a first application head and delivering at least one second micro-droplet to the substrate from a second application head.
55. 55. The method of claim 54, wherein the at least one second microdroplet is smaller in size than the first plurality of microdroplets.
56. 56. The method of any one of claims 54-55, further comprising determining in real time when delivery of a selected one of the at least one second microdroplet to the substrate results in the total amount of API being greater than the predetermined target amount of API.
57. 57. The method of any one of claims 55-56, comprising ceasing the delivering step based on determining, in real time, when delivery of selected ones of the at least one second microdroplet to the substrate causes the total amount of API to be greater than the predetermined target amount of API.
58. 58. The method of claim 57, comprising performing the aborting step prior to delivering the selected microdroplets if the delivery of the selected microdroplets would result in the total amount of the API being greater than the sum of the predetermined target amount of API and one-half the predicted amount of API in the selected microdroplets.
59. 60. The method of claim 58, comprising enabling the selected microdroplet to be delivered if the delivery of the selected microdroplet would result in the total amount of the API being less than the sum of the predetermined target amount of API and one-half of a predicted amount of API in the selected microdroplet.
60. 60. The method of claim 59, comprising performing the discontinuing step immediately after delivering the selected microdroplets if the total amount of API is greater than the predetermined target amount of API.
61. 61. The method of any one of claims 54 to 60, wherein the imaging step includes imaging the first plurality of microdroplets with a first camera and imaging the at least one second microdroplet with a second camera.
62. 62. The method of any one of claims 54 to 61, wherein the at least one second microdroplet is delivered while the step of delivering the first plurality of microdroplets is being performed.
63. 62. The method of any one of claims 54 to 61, wherein the at least one second microdroplet is delivered only after the step of delivering the first plurality of microdroplets is completed.
64. 62. The method of any one of claims 54 to 61, wherein the at least one second microdroplet comprises a plurality of second microdroplets.
65. 65. The method of any one of claims 44 to 64, wherein the delivering step comprises delivering between 10 and 500 microdroplets to the substrate.
66. 45. The method of claim 44, wherein the delivering step comprises delivering between 2 and 500 microdroplets to the substrate.
67. 67. The method of any one of claims 44 to 66, wherein the substrate is a bite-sized edible food product.
68. 68. The method of any one of claims 44 to 67, wherein the imaging step is performed at a location along the path where the microdroplet becomes substantially spherical.
69. 69. The method of any one of claims 44 to 68, wherein the liquid contains the API at a concentration ranging from about 50 micrograms per microliter of solution to about 1 milligram per microliter of solution.
70. 70. The method of any one of claims 44 to 69, wherein each of the microdroplets contains a respective minute amount of the API in the range of about 0.1 micrograms to about 10 milligrams.
71. 70. The method of any one of claims 44 to 69, wherein the microdroplets each have a volume in the range of about 2 nanoliters to about 10 microliters.
72. 70. The method of any one of claims 45 to 69, further comprising the steps of comparing an actual amount of at least one API in the microdroplets to a predetermined target amount, and adjusting a parameter that alters the amount of each of the APIs in the microdroplets if the amount of API is outside an acceptable range from the predetermined amount of API.
73. 73. The method of claim 72, comprising decreasing at least one of a stroke length, a stroke rate, or other system parameter if the actual amount of API exceeds the tolerance range from the predetermined amount of API.
74. 74. The method of any one of claims 72 to 73, comprising increasing at least one of a stroke length, a stroke rate, or other system parameter if the actual amount of API falls below the tolerance range from the predetermined amount of API.
75. 75. The method of any one of claims 44 to 74, comprising generating and delivering the microdroplets under a selected set of parameter settings that are determined to have a reduced impact on the size of the amount of API in each of the microdroplets when adjusted, compared to the impact of adjusting the setting if not included in the set of parameters.
76. 76. The method of any one of claims 44 to 75, wherein determining the total amount of the API comprises measuring a size of each of the microdroplets during the imaging step.
77. 77. The method of claim 76, wherein the step of determining the total amount further comprises: calculating a respective amount of API in the microdroplets based on the respective measured sizes; and adding together each of the calculated respective amounts of API.
78. 78. The method of any one of claims 44 to 77, wherein the imaging step comprises optical imaging or detection, including any one or more of: performing UV imaging or detection of the microdroplet, reflectometry of the microdroplet, interferometry of the microdroplet, Raman and / or resonance Raman scattering of the microdroplet, UV fluorescence of the microdroplet, infrared imaging of the microdroplet, and X-ray scattering of the microdroplet.
79. 79. The method of any one of claims 44 to 78, wherein the imaging step is performed along a trajectory that intersects with the path.
80. 80. The method of claim 79, wherein the trajectory is substantially perpendicular to the path.
81. 81. The method of claim 80, wherein the trajectory is at an oblique angle to the path.
82. 82. The method of any one of claims 42 to 81, further comprising varying a size of the microdroplets by varying a parameter along a substantially "S" shaped transition from an initial parameter value to a final parameter value.
83. 83. The method of any one of claims 42-82, wherein the API comprises cannabis.
84. 84. The method of claim 83, wherein the cannabis comprises cannabinoids including either or both of CBD and TCH.
85. 85. The method of any one of claims 42-84, wherein the API comprises at least one flavonoid.
86. 86. The method of any one of claims 42-85, wherein the API comprises at least one terpene.
87. 83. The method of any one of claims 42-82, wherein the API comprises at least one of psilocybin and psilocin.
88. 83. The method of any one of claims 42-82, wherein the API comprises a synthetic opioid.
